



Vaccines and Global Health: The Week in Review
29 May 2021 :: Issue 609
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 23,000 entries.***

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents *[click on link below to move to associated content]*

- A. Milestones :: Perspectives :: Featured Journal Content
- B. Emergencies
- C. [WHO; CDC \[U.S., Africa, China\]](#)
- D. [Announcements](#)
- E. [Journal Watch](#)
- F. [Media Watch](#)

Milestones :: Perspectives :: Research

Editor's Note:

As is obvious to all, the sheer volume of strategic announcements, regulatory actions, country program decisions, commentary, and, indeed, misinformation around COVID response continues at extraordinary levels. Our weekly digest strives to present a coherent and comprehensive snapshot, but cannot be exhaustive. If you recognize a missed strategic development, a new source of rigorous analysis, or an insight/commentary that would benefit our common understanding, please advise me...we will review all suggestions and consider for inclusion in a subsequent edition:

david.r.curry@ge2p2global.org

.....
.....

World Health Assembly

Seventy-fourth World Health Assembly #WHA74

24 May to 1 June 2021

Theme: Ending this pandemic, preventing the next: building together a healthier, safer and fairer world.

:: Provisional agenda

:: Watch live WHA74 sessions

:: Documents

.....

Double COVID-19 Vaccine Production, Bolster Primary Health-Care Systems to Prepare for Next Global Emergency, Secretary-General Tells World Health Assembly

24 May 2021 SG/SM/20740

[Excerpt focused on COVID vaccines/vaccination]

...We are at war with a virus. We need the logic and urgency of a war economy, to boost the capacity of our weapons. On Friday, I called on the [Group of 20] (G20) to set up a task force that brings together all countries with vaccine production capacities, the World Health Organization, the ACT-Accelerator partners and international financial institutions, able to deal with the pharmaceutical companies and other key stakeholders.

It should aim to at least double manufacturing capacity by exploring all options, from voluntary licenses and technology transfers to patent pooling and flexibility on intellectual property rights. The task force should address equitable global distribution by using the ACT-Accelerator and its COVAX Facility. The G20 task force should be co-convened at the highest levels by the major Powers who hold most of the global supply and production capacity, together with the multilateral system. I am ready to mobilize the entire United Nations system to support this effort...

.....

Director-General's opening remarks at the World Health Assembly - 24 May 2021

[Excerpt focused on COVID vaccines/vaccination]

...The ongoing vaccine crisis is a scandalous inequity that is perpetuating the pandemic. More than 75% of all vaccines have been administered in just 10 countries. There is no

diplomatic way to say it: a small group of countries that make and buy the majority of the world's vaccines control the fate of the rest of the world.

The number of doses administered globally so far would have been enough to cover all health workers and older people, if they had been distributed equitably. We could have been in a much better situation.

I understand that every government has a duty to protect its own people. I understand that every government wants to vaccinate its entire population. That's what we want too. And in time, there will be enough supply for everyone, including those at lower risk.

But right now, there is not enough supply. **Countries that vaccinate children and other low-risk groups now do so at the expense of health workers and high-risk groups in other countries. That's the reality.**

At the Executive Board meeting in January, I issued a challenge to see vaccination of health workers and older people underway in all countries within the first 100 days of the year. That target was very nearly achieved. But the number of doses available to COVAX remains vastly inadequate.

COVAX works. We have shipped every single one of the 72 million doses we have been able to get our hands on so far to 125 countries and economies. But those doses are sufficient for barely 1 percent of the combined population of those countries.

So today I am calling on Member States to support a massive push to vaccinate at least 10 percent of the population of every country by September, and a "drive to December" to achieve our goal of vaccinating at least 30 percent by the end of the year. This is crucial to stop severe disease and death, keep our health workers safe and reopen our societies and economies.

Sprinting to our September goal means we must vaccinate 250 million more people in low- and middle-income countries in just four months, including all health workers and the most at-risk groups as the first priority. These are the minimum targets we should aim for.

At the G20 Global Health Summit on Friday, IMF Managing Director Kristalina Georgieva proposed vaccinating 40 percent of the world's population by the end of the year and 60 percent by mid-2022. We are in discussions with the IMF, Member States and our partners about how to make these ambitious targets achievable.

Here's how the "Drive to December" must happen:

First, share doses through COVAX, now. I welcome the commitments made by Member States to donate doses, including the important announcements made at the G20 Global Health Summit on Friday.

But to achieve the goals for September and the end of the year, we need hundreds of millions more doses, we need them to go through COVAX, and we need them to start moving in early June. Manufacturers must play their part, by ensuring any country that wants to share doses through COVAX can do it within days, not months.

I call on all manufacturers to give COVAX first right of refusal on new volume of vaccines, or to commit 50% of their volumes to COVAX this year. And we need every country that receives vaccines to use them as quickly as possible. No dose can lay idle, or worse, be thrown away. Country-level preparations to reach their populations must move as fast as vaccines.

Second, scale-up manufacturing. The bottom line is that we need a lot more doses, we need them fast, and we must leave no stone unturned to get them. Several manufacturers have said they have capacity to produce vaccines if the originator companies are willing to share licenses, technology and know-how. I find it difficult to understand why this has not happened yet.

I thank India and South Africa for their initiative at the World Trade Organization to waive intellectual property protections for COVID-19 products, and I thank those countries that are supporting these efforts. And we urge Member States and manufacturers to join C-TAP, the WHO COVID-19 Technology Access Pool, which provides a powerful mechanism for sharing licenses in a non-exclusive, transparent way. I thank Prime Minister Pedro Sanchez for his commitment that Spain will join C-TAP, and we expect more good news in the coming days.

And third, fully fund the ACT Accelerator. There remains an 18.5 billion US dollar gap in the ACT Accelerator.

Ultimately, the pandemic has shown clearly that in an emergency, low and lower-middle income countries cannot rely on imports from vaccine-producing countries. I welcome the draft resolution on strengthening local production of medicines and other health technologies that Member States will consider at this Assembly.

I would also like to take this opportunity to express my deep appreciation to President Biden for reversing the decision to take the United States out of WHO, for donating US\$4 billion to COVAX, and also for their announcement that they will donate 80 million vaccine doses globally – these are the largest contributions announced – and for supporting the intellectual property waiver...

.....

[Update from the Seventy-fourth World Health Assembly – 29 May 2021](#)

29 May 2021 *News release*

New resolutions on:

- :: Local production of medicines
- :: Ending violence against children
- :: Addressing social determinants of health

Strengthening local production of medicines and other health technologies to improve access

Member State requests for WHO's support in strengthening local production have been increasing in recent years. The COVID-19 pandemic has only served to highlight even more the urgent need for enhancing quality manufacturing capacity in all regions of the world, including for innovative, highly effective health products such as mRNA technologies. Such capacity is necessary to address or even avert future public health emergencies and to improve access to health products in general through stronger health systems.

Sponsored by more than 100 countries, today's resolution specifically calls for a more comprehensive, all-of-government approach, national strategies and action plans, an enabling business

environment, human capital development, multi-stakeholder collaboration and engagement in regional and global networks.

WHO has already committed to holding the first ever World Local Production Forum in June this year, convening countries, partners and other stakeholders to discuss strategies to promote local production to improve access to health products during the current pandemic and beyond...

Tackling social determinants of health

...The resolution aims to strengthen action globally and within countries on the social determinants of health; to reduce health inequities by involving all sectors in taking concrete action to improve living conditions and reduce social inequalities; and improve monitoring of social determinants and health inequities. The resolution lists actions to be taken by governments, civil society, international organizations, intergovernmental organizations, the private sector and the WHO Secretariat, including in continuing efforts to combat the COVID-19 pandemic and in future recovery efforts.

Update from the Seventy-fourth World Health Assembly – 28 May 2021

28 May 2021 *News release*

- :: New resolutions on the health and care workforce and strategic directions for nursing and midwifery
- :: Decisions on patient safety; health, environment and climate change; chemicals management; coordination of work on noncommunicable diseases
- :: Global Action Plan for Healthy Lives and Wellbeing for All
- :: Prevention of sexual exploitation, abuse and harassment

World Health Assembly adopts new resolution on malaria

28 May 2021 *Departmental news*

The World Health Assembly, the main governing body of the World Health Organization, has adopted a new resolution that aims to revitalize and accelerate efforts to end malaria, a preventable and treatable disease that continues to claim more than 400 000 lives annually...

The resolution urges Member States to step up the pace of progress through plans and approaches that are consistent with WHO's updated global malaria strategy and the WHO Guidelines for malaria. It calls on countries to extend investment in and support for health services, ensuring no one is left behind; sustain and scale up sufficient funding for the global malaria response; and boost investment in the research and development of new tools...

Update from the Seventy-fourth World Health Assembly – 27 May 2021

27 May 2021 *News release*

- :: New resolutions on diabetes, health for people with disabilities; malaria; oral health
- :: Decisions on eye care; HIV, Hepatitis and STIs; neglected tropical diseases, noncommunicable diseases
- :: WHO programme budget approved 2022-2023

IOAC statement at the Seventy-fourth World Health Assembly, 25 May 2021

Independent Oversight and Advisory Committee for the WHO Health Emergencies Programme - IOAC
25 May 2021 *Statement*

.....
.....

COVID Global Response – Calls to Action, Joint Statements

Secretary-General Asks Private Sector to Fund Vaccine Equity, Help Put Humanity on 'War Footing' against COVID-19, at Business Leaders' Event

27 May 2021 SG/SM/20749

Stressing Africa Has Received 2 Per Cent of COVID-19 Vaccines, Secretary-General Urges Developed Countries to Support Continent's Pandemic Recovery, in Observance Message

24 May 2021 SG/SM/20737

.....

No-one is safe until everyone is safe – why we need a global response to COVID-19

Joint Statement – Signatories below

GENEVA, 23 May 2021 – *[Editor's text bolding]*

"Equitable vaccine distribution is a humanitarian imperative.

"There is a choice. The world of the next 10 years can be one of greater justice, abundance and dignity. Or it can be one of conflict, insecurity and poverty. We are at a turning point.

"COVID-19 has been a truly global crisis in which we all have shouldered a burden. In many cases this has caused us to reflect on those longer injustices that have perpetuated in parts of the world where the pandemic is yet another layer of misery, instability and unrest. These inequalities have been exposed and exacerbated by the impact of the pandemic, both between and within countries. The effects will be felt on a global scale for years to come.

"The impact of a catastrophe like the COVID-19 pandemic is measured in the tragedy of individual loss and death, as well as the national and global disruption to almost every part of life. No country in the world has been untouched.

"Variants of the virus, potentially more infectious and resistant to vaccines, will continue to threaten us if they are not controlled now. Those of us who have signed this declaration represent organizations with roots in communities across the world. We work closely with those affected by conflict, disaster and famine, and know the immense challenges they face – but also of their resilience even in the worst of situations.

"In 2021, the world economy is facing the worst downturn since 1945. For some countries this will sharply increase poverty and suffering. For others it means hunger and death. The fallout from the pandemic will be with us for a long time to come. There will be a continued economic impact, with all the human suffering that brings. A generation of children, especially girls, have left school and will not return.

"The world is facing the challenge of how to reverse these devastating dynamics with health being a key part of such a response. **We advocate here for 'Health for All', where each person's life is valued, and every person's right to healthcare is upheld. People not only need vaccinations**

– they need access to healthcare workers who are skilled and equipped to deliver adequate medical support.

"We need to build a world where each community, regardless of where they live, or who they are, has urgent access to vaccinations: not just for COVID-19, but also for the many other diseases that continue to harm and kill. As the pandemic has shown us, in our interdependent world no one is safe until everyone is safe.

"We have a choice: vaccine nationalism or human solidarity.

"Thanks to effective international action, several vaccines have been produced. The World Health Organisation, GAVI and CEPI are leading the COVAX initiative, which is currently the best effort we have to ensure that vaccines reach people around the world. **However, COVAX is only intended to cover 20% of the global population– the most vulnerable in lower-income countries – by the end of 2021 and it is not yet clear if it will meet this target.** Meanwhile studies show that if we focus only on vaccinating our own populations, the world risks global GDP losses of up to US\$9.2 trillion (with half of that cost being incurred by high income countries) this year alone.

"But it is not just a matter of money. **In order to achieve wider global vaccination, complex logistical, infrastructure and scaling issues must be addressed.** The Access to COVID-19 Tools (ACT) Accelerator is focused on providing a means to accelerate the development, manufacturing and distribution of COVID-19 diagnostic and treatment products. The ACT recognizes and aims to address the requirement for information sharing - whether about technology, intellectual property or manufacturing.

"However, more needs to be done. The sharing of information, the transfer of technology and the strengthening of manufacturing processes, to name a few, require the active involvement of States and the private sector.

"We therefore call on world leaders to:

- 1. Ensure equitable access to vaccines between countries** by providing vaccines, sharing knowledge and expertise, and fully funding the Access to COVID-19 Tools (ACT) Accelerator, which is working to provide equitable access to and implementation of COVID-19 diagnostics, therapeutics, and vaccines.
- 2. Ensure equitable access to vaccines within countries** by ensuring all sectors of the population are included in national distribution and vaccination programs, regardless of who they are or where they live, including stigmatized and marginalized communities for whom access to healthcare might not be straightforward.
- 3. Support countries financially, politically and technically to ensure that curbing COVID-19 is not a standalone goal,** and instead is one important element of a broader health strategy, implemented alongside communities to bring longer-term improvements to people's health and access to healthcare. We are committed, in our different institutions, to offering all the help we can to support actions by communities and authorities.

"It is time for decisive leadership. Countries and organizations across the world have a once-in-a-generation opportunity to address global inequality and reverse some of the

fallout from the past year. In doing so, they will bring hope not only for the poorest in the world, but for us all."

####

The Most Reverend Justin Welby, Archbishop of Canterbury
Peter Maurer, President of the International Committee of the Red Cross
Bishop Ivan M Abrahams, General Secretary of the World Methodist Council
HE Elder Metropolitan Emmanuel of Chalcedon, Ecumenical Patriarchate
The Reverend Dr Chris Ferguson, General Secretary of the World Communion of Reformed Churches
Dr Tedros Adhanom Ghebreyesus, WHO Director-General
Filippo Grandi, United Nations High Commissioner for Refugees
Henrietta H. Fore, Executive Director, UNICEF
The Reverend Dr Martin Junge, General Secretary of the Lutheran World Federation
Dr Azza Karam, Secretary-General, Religions for Peace
Francesco Rocca, President of the International Federation of Red Cross and Red Crescent Societies
Rabbi David Rosen, Co-President, Religions for Peace
Sheikh Ahmed al-Tayeb, The Grand Imam of al-Azhar
HE Cardinal Peter Turkson, Prefect of the Dicastery for Promoting Integral Human Development, Rome

.....
.....

COVAX Joint Statement: Call to action to equip COVAX to deliver 2 billion doses in 2021

Joint statement by:

:: Dr Richard Hatchett, CEO, Coalition for Epidemic Preparedness Innovations (CEPI),
:: Dr Seth Berkley Chief Executive Officer, Gavi, the Vaccine Alliance (Gavi),
:: Dr Tedros Adhanom Ghebreyesus Director-General, World Health Organization (WHO) and
:: Henrietta Fore, Executive Director, UNICEF

NEW YORK/GENEVA/OSLO, 27 May 2021 - "Countries that are advanced in their vaccination programmes are seeing cases of COVID-19 decline, hospitalisations decrease and early signs of some kind of normality resume. "However, the global picture is far more concerning.

"At no point in this pandemic have we seen such an acute need to look to the future challenges and not rest on the patchy achievements made so far. "We are seeing the traumatic effects of the terrible surge of COVID-19 in South Asia – a surge which has also severely impacted global vaccine supplies.

"We are also witnessing why access to vaccines before a surge occurs is so important. For that reason, we must focus on ensuring countries who have not benefitted from these life-saving tools do so now, and with urgency.

"As the global mechanism for equitable access to COVID-19 vaccines, COVAX has proven it works. Designed and implemented in the midst of an unprecedented global public health crisis, it has delivered over 70 million doses to 126 countries and economies around the world since February – from remote islands to conflict settings – managing the largest and most complex rollout of vaccines in history. Over 35 countries received their first COVID-19 vaccine doses thanks to COVAX.

"However, the terrible surge of the virus in India has had a severe impact on COVAX's supply in the second quarter of this year, to the point where, by the end of June we will face a shortfall of 190 million doses.

"Even though COVAX will have larger volumes available later in the year through the deals it has already secured with several manufacturers, **if we do not address the current, urgent shortfall the consequences could be catastrophic.** "But we can meet this challenge with concerted action and global leadership.

"Millions of dollars and doses were committed to COVAX on 21 May, bringing the total of doses pledged so far to more than 150 million. At the World Health Assembly, governments have been united in recognising the political and financial urgency of supporting COVAX with doses and dollars. It is now imperative to build on this momentum to secure full funding for COVAX and more vaccines – right now – for lower-income countries at the Advance Market Commitment Summit on 2 June.

"If the world's leaders rally together, the original COVAX objectives – delivery of 2 billion doses of vaccines worldwide in 2021, and 1.8 billion doses to 92 lower-income economies by early 2022 are still well within reach.

"But it will require governments and the private sector to urgently unlock new sources of doses, with deliveries starting in June, and funding so we can deliver. COVAX has the infrastructure in place to facilitate and coordinate this complex global effort.

"To enable COVAX to deliver on the promise of global equitable access, we call for the following immediate actions:

:: Fund the Gavi COVAX Advance Market Commitment (AMC). The AMC mechanism is how COVAX provides doses to lower-income economies. Thanks to the generosity of its donors, the AMC has already secured 1.3 billion doses for delivery in 2021. This is enough to protect the most at-risk population groups: health workers, the elderly and those with underlying health conditions. We need an additional \$2 billion to lift coverage in AMC countries up to nearly 30%, and we need it by [June 2](#) to lock in supplies now so that doses can be delivered through 2021, and into early 2022.

:: Share doses, now. The pandemic has just taken a frightening new turn, as a deadly surge of cases rages across South Asia and other hotspots. Countries with the largest supplies should redirect doses to COVAX now, to have maximum impact.

"We are starting to see countries stepping forward with doses, with the United States and Europe collectively pledging to share 180 million doses. But we still need more, we need them to go through COVAX, and we need them to start moving in early June. At least one billion doses could be shared by wealthy countries in 2021.

"COVAX's need for doses is greatest right now. Countries with higher coverage rates, which are due to receive doses soon should swap their places in supply queues with COVAX so that doses can be equitably distributed as quickly as possible.

:: Free up supply chains by removing trade barriers, export control measures, and other transit issues that block, restrict or slow down the supply and distribution of COVID-19 vaccines, raw materials, components and supplies.

"Now more than ever, at the peak of the pandemic, we need ambitious, global solutions. When it comes to worldwide vaccine distribution, COVAX is the only initiative capable of rising to the challenge of this moment.

"It's understandable that some countries want to press ahead and vaccinate all of their populations. By donating vaccines to COVAX alongside domestic vaccination programmes, the most at-risk populations can be protected globally, which is instrumental to ending the acute phase of the pandemic, curbing the rise and threat of variants, and accelerating a return to normality.

COVAX is hugely appreciative to France, Germany, Italy, New Zealand, Spain, Sweden and the UAE for their initial commitments to donate doses through COVAX, and to Canada for funding to support the design and operationalization of the COVAX dose sharing mechanism. We also welcome announcements by the USA, Norway, Croatia, Romania, Australia and Portugal to donate doses to countries in need and we put COVAX forward as the proven mechanism for global, rapid and equitable distribution to facilitate this.

"Since COVAX was established in mid-2020, it has had the support and resources of 192 of the world's economies. This tremendous vote of confidence has enabled us to demonstrate our ability to deliver an unprecedented global rollout. It's time to finish the job."

#####

Notes to editors:

The goal of sharing at least 1 billion excess doses by the end of 2021 is based on a Bill & Melinda Gates Foundation analysis of current projections of excess doses globally. Even under conservative estimates, the analysis finds that after sharing 1 billion doses, wealthy countries would have sufficient doses to vaccinate 80% of their populations 12 years and older in 2021. *[No citation/link provided]*

.....
.....

COVID – Region Assessment: South Asia

UNICEF News note

Geneva Palais Briefing Note on COVID-19 in South Asia

This is a summary of what was said by UNICEF Regional Director for South Asia, George Laryea-Adjei – to whom quoted text may be attributed – at today's press briefing at the Palais des Nations in Geneva

GENEVA/KATHMANDU, 25 May 2021 - "The scenes we are witnessing in South Asia are unlike anything our region has seen before. Family members of patients are carrying oxygen cylinders inside hospitals, risking their own lives in hopes of saving a loved one. Exhausted health workers are working sixteen-hour days, unable to pay individual attention to every patient under their care. We are faced with a real possibility of fragile health systems collapsing.

"South Asia is home to almost 2 billion people, and more than a quarter of the world's children. The region now accounts for half of known new infections globally. Over three new COVID-19 infections are being recorded every second. Mortality in the region has risen sharply, with one person dying every 17 seconds from COVID-19.

"The sheer scale and speed of this new surge of COVID-19 is outstripping countries' abilities to provide life-saving treatment.

"Just last week, India recorded the highest number of daily deaths ever in the history of the COVID-19 pandemic: 4,529. "Neighboring Nepal has experienced case positivity rates as high as 47 per cent. In Banke district, there are reports of nurses taking care of 20 critically ill patients on their own. "Sri Lanka is recording new highs in COVID-19 cases and deaths on a daily basis. 88% of hospital beds are currently in use.

"Maldives is witnessing an unprecedented peak in cases, particularly in its capital, Malé. Its health system is under severe strain and the government has had to increase bed capacity in medical facilities. "Bangladesh, Pakistan, Afghanistan, and Bhutan could all face similar devastating surges.

"We need to act fast to save lives now. But we also need to do everything within our power to keep the critical health care services that children and mothers so heavily rely on running.

"During the first wave of the pandemic, an estimated 228,000 children and 11,000 mothers across South Asia died due to severe disruptions to essential health services, such as routine immunization, care during pregnancy and childbirth, and treatment for pneumonia and malnutrition. With a surge that is four times the size of the first, we are facing a real possibility of a severe spike in child and maternal deaths in South Asia.

"We simply cannot let this happen...

.....
.....

COVID Vaccines – Customs/Cross-border Movement/Regulations

[The WCO Secretariat Note on the cross-border movement of vaccines enhanced with further guidance and good practices](#)

World Customs Organization – WCO

28 May 2021

The World Customs Organization (WCO) published the 2nd edition of the Secretariat Note on the Role of Customs in facilitating and securing the cross-border movement of situationally critical medicines and vaccines that enhances the inaugural version launched on 25 February 2021.

WCO Secretary General Dr. Kunio Mikuriya stated, "How to achieve **equitable distribution of COVID-19 vaccines is critical, and Customs administrations around the world should support global efforts by not only facilitating the cross-border movement of the vaccines themselves, but also by speeding up and facilitating the Customs clearance of the raw materials and components used in the vaccine manufacturing process.**" He added that "This will greatly contribute to the efforts to scale up vaccine manufacturing and the 2nd edition of the Secretariat Note highlights the critical role Customs".

The document contains further guidance on practical ways to implement the measures of the December 2020 Resolution of the Customs Co-operation Council on the Role of Customs in facilitating the cross-border movement of situationally critical medicines and vaccines, a greater number of

Members' case studies, and operational guidelines developed for the WCO Membership by the Australian Border Force.

The guidance outlined in the Secretariat Note draws upon relevant WCO instruments and tools, Members' good practices and insights gathered as a result of the collaboration with other international organizations, the pharmaceutical industry, logistics providers and other relevant private sector entities.

The Secretariat Note is designed to be a living document that will be enhanced with more Members' practices and further practical guidance as WCO Members and the industry gain experience and share information with the WCO Secretariat on the Customs clearance of COVID-19 vaccines, related supplies, inputs and equipment.

[Excerpt from 2nd edition of the Secretariat Note, page 6]

c. Practical ways to implement measure 10 of the Resolution are to:

:: Nominate contact points/enquiry points in Customs and other relevant government agencies to exchange information in a timely manner and respond to requests by supply chain stakeholders.

:: Establish a task force with the participation of all relevant government agencies, including Customs, as well as relevant private sector representatives.

:: Coordinate through the National Committee on Trade Facilitation (NCTF).

:: Engage with all relevant government agencies and supply chain stakeholders to develop Standard Operating Procedures for the exportation and importation of situationally critical medicines, vaccines and related supplies, inputs and equipment.

:: Perform all border clearance procedures through a Single Window facility.

:: Cooperate with health authorities and supply chain stakeholders to provide training to operational Customs staff.

.....
.....

COVID Vaccines – OCHA:: HDX

[COVID-19 Data Explorer: Global Humanitarian Operations](#)

COVID-19 Vaccine Roll-out

May 29, 2021 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

Global COVID-19 Figures: 168M total confirmed cases; 3.5M total confirmed deaths

Global vaccines administered: 1.81B [1.59B]

Number of Countries: 26 [26]

COVAX First Allocations (Number of Doses): 73M [73M]

COVAX Delivered (Number of Doses): 15M [15M]

Other Delivered (Number of Doses): 24M [24M]

Total Delivered (Number of Doses): 40M [40M]

Total Administered (Number of Doses): 27M [23M]

.....
.....

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Weekly Epidemiological and Operational updates

Last update: 29 May 2021

Confirmed cases :: 169 118 995 [week ago: 165 772 430]
Confirmed deaths :: 3 519 175 [week ago: 3 437 545]
Vaccine doses administered: 1 546 316 352 [week ago: 1 448 242 899]

.....

Weekly operational update on COVID-19 - 24 May 2021

In this edition of the COVID-19 Weekly Operational Update, highlights of country-level actions and WHO support to countries include:

- :: Medical supplies reach Indian states and Union Territories
- :: Egypt and Philippines receive additional shipments of COVID-19 vaccines through the COVAX Facility
- :: Strengthening quality assurance and biosafety for SARS-CoV-2 sample collection sites in Azerbaijan
- COVID-19 posing unprecedented threat on war-torn Yemen
- :: Online training on vaccination to frontline workers in Uruguay
- :: WHO EPI-WIN hosted discussion for youth networks on mental health and how ten years of
- :: Pandemic Influenza Preparedness (PIP) strengthened capacities to support the COVID-19 response
- :: Regular updates on WHO's resource requirements and funds received to support countries in implementing the COVID-19 Strategic Preparedness and Response Plan 2021, WHO/PAHO procurement of critical supplies, and implementation of the Unity Studies

Weekly epidemiological update on COVID-19 - 25 May 2021

Overview

For the second successive week, the number of COVID-19 cases globally remains at the highest levels since the beginning of the pandemic with over 5.7 million new weekly cases, following nine consecutive weeks of increases. New deaths continue to increase for the seventh consecutive week, with over 93 000 deaths. The South-East Asia Region continues to report marked increases in both case and death incidences.

In this edition, special focus updates are provided on:

- :: World Hand Hygiene Day, 5 May 2021
- :: WHO partnership with SeroTracker — synthesizing “real-time” seroprevalence data to support global pandemic response
- :: SARS-CoV-2 variants

[Excerpt, p. 7]

Special Focus: Update on SARS-CoV-2 variants

WHO, in collaboration with national authorities, institutions and researchers, routinely assesses if variants of SARS-CoV-2 result in changes in transmissibility, clinical presentation and severity, or if they result in changes in public health and social measures (PHSM) implementation by national health authorities. Systems have been established to detect “signals” of potential variants of concern (VOCs) or variants of interest (VOIs) and assess these based on the risk posed to global public health (see also working definitions). National authorities may choose to designate other variants of local interest/concern. Detailed information on currently circulating VOCs and VOIs is available in previously published editions of the Weekly Epidemiological Update. Here we provide a brief update on the

geographical distribution of the three VOCs as of 4 May 2021, as well as an update on detected VOIs (Table 2).

As surveillance activities to detect SARS-CoV-2 variants are strengthened at local and national levels, including by strategic genomic sequencing, the number of countries/areas/territories (hereafter countries) reporting VOCs and VOIs has continued to increase. Since our last update on 27 April, VOC 202012/01 has been detected in three additional countries, variant 501Y.V2 in ten additional countries, and variant P.1 has been reported in three additional countries. As of 4 May, a total 142 countries have reported VOC 202012/01 (Figure 3), 97 countries variant 501Y.V2 (Figure 4), and 56 countries variant P.1 (Figure 5) – see also Annex 2. The information presented here should be interpreted with due consideration of surveillance limitations, including differences in sequencing capacities and prioritization of samples for sequencing between countries.

Table 2: SARS-CoV-2 variants of concern (VOC) and variants of interest (VOI), as of 4 May 2021*

	Nextstrain clade	Pango lineage	GISAID clade	Alternate name	First detected in	Earliest samples	Characteristic spike mutations
VOC	20I/501Y.V1	B.1.1.7	GR/501Y.V1	VOC 202012/01 [†]	United Kingdom	Sep 2020	69/70del, 144del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H
	20H/501Y.V2 [†]	B.1.351	GH/501Y.V2 [†]	VOC 202012/02	South Africa	Aug 2020	D80A, D215G, 241/243del, K417N, E484K, N501Y, D614G, A701V
	20J/501Y.V3	B.1.1.28.1, alias P.1 [†]	GR/501Y.V3	VOC 202101/02	Brazil and Japan	Dec 2020	L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G H655Y, T1027I, V1176F
VOI	20A/S.484K	B.1.525	G/484K.V3	-	United Kingdom and Nigeria	Dec 2020	Q52R, A67V, 69/70del, 144del, E484K, D614G, Q677H, F888L
	20C/S.452R	B.1.427/ B.1.429	GH/452R.V1	CAL.20C/L452R	United States of America	Jun 2020	S13I, W152C, L452R, D614G
	20B/S.484K	B.1.1.28.2, alias P.2	GR	-	Brazil	Apr 2020	E484K, D614G, V1176F
	-	B.1.1.28.3, alias P.3	-	PHL-B.1.1.28	Philippines and Japan	Feb 2021	141/143del, E484K, N501Y, D614G P681H, E1092K, H1101Y, V1176F
	20C	B.1.526 with E484K or S477N	GH	-	United States of America	Nov 2020	L5F, T95I, D253G, D614G, A701V, E484K or S477N
	20C	B.1.616	GH	-	France	Jan 2021	H66D, G142V, 144del, D215G, V483A, D614G, H655Y, G669S, Q949R, N1187D
	-	B.1.617	G/452R.V3	-	India	Oct 2020	L452R, D614G, P681R, ±E484Q

[†]While work is ongoing to establish standardized nomenclature for key variants, these are the names by which WHO will refer to them in this publication.

.....
.....

Draft landscape and tracker of COVID-19 candidate vaccines

28 May 2021 | Publication

The COVID-19 candidate vaccine landscape and tracker database compiles detailed information on COVID-19 vaccine candidates in development.

The landscape is updated regularly - twice a week (Tuesday and Friday, 17:00 CET).

Download: https://cdn.who.int/media/docs/default-source/blue-print/28.05.2021-novel-coronavirus-landscape-covid-19.xlsx.zip?sfvrsn=e352acfa_3&download=true














Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 28 May 2021

For 19 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date

[click on the link above for full scale view]

28 May 2021

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Anticipated decision date***
1.	 BNT162b2	BNT162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside modified mRNA	✓	✓	✓	Finalized	31/12/20
2.		AZD1222	EMA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	Accepted core data Data for Covax sites expected in April 2021 onwards	Finalized Finalized: SK-Catalent Wuxi (DS) Other sites	16 April 2021 16 April 2021 As submitted
3.		AZD1222	MFDS KOREA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
4.		Covishield (ChAdOx1_nCoV-19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
5.		Ad26.COV2.S	EMA	Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	✓	✓	Core data Additional sites: - Aspen South Africa - Other sites	Finalized (US +NL sites) - Ongoing* - Awaited	12 March 2021 - June 2021 - As submitted
6.		mRNA-1273	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	✓	✓	Finalized	30 April 2021
7.		SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	Finalized	07 May 2021
8.		SARS-CoV-2 Vaccine (Vero Cell), Inactivated	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	In progress	Early June 2021
9.		Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings held.	"Rolling" submission of clinical and CMC data has started.	Additional data (Non-CLIN, CLIN, CMC) Required. Inspections in April, May and June 2021	Will be set after all data is submitted and inspections completed.
10.		Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	✓	✓	Rolling data starting June 2021		
11.		NVX-CoV2373/Covovax	EMA	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant	✓	✓			
12.		Inactivated SARS-CoV-2 Vaccine (Vero Cell)	NMPA	Inactivated, produced in Vero cells	EOI submitted on 30 April and more on 26 May 2021.	Requested information just received			
13.		Zorecimeran (INN) concentrate and solvent for dispersion for injection; Company code: CVnCoV/CV07050101	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	Submitted EOI on 12 April	Submitted EOI on 12 April	Planned for 15 July 2021, based on company request		
14.	Vector State Research Centre of Virology and Biotechnology	EpiVacCorona	Russian NRA	Peptide antigen	Letter received not EOI. Reply sent on 15/01/2021				
15.	Zhifei Longcom, China	Recombinant Novel Coronavirus Vaccine (CHO Cell)	NMPA	Recombinant protein subunit	Response to 2 nd EOI sent 29 Jan 2021. Additional information requested.				
16.	IMBCAMS, China	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	NMPA	Inactivated	Not accepted, still under initial development				
17.	Bharat Biotech, India	COVAXIN	DCGI	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	Submitted EOI on 19/04/2021. More information required.	To be planned in June 2021			
18.	Clover Biopharmaceuticals	SCB-2019	EMA	Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein	In discussion on submission strategy and timelines				
19.	BioCubaFarma - Cuba	Soberana 01, Soberana 02, Soberana Plus	CECMED	SARS-CoV-2 spike protein conjugated chemically to meningococcal B or tetanus toxoid or Aluminum	Awaiting information on strategy and timelines for submission.				

1. Beijing Institute of Biological Products Co Ltd
2. Wuhan Institute of Biological Products Co Ltd

* Dossier Submission dates: more than one date is possible because of the rolling submission approach. Dossier is accepted after screening of received submission.

**Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant; 4. Risk-benefit decision 5. Final decision made

*** Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors' questions are submitted.



.....

COVID Vaccine Developer/Manufacturer Announcements *[organizations from WHO EUL/PQ listing above]*

AstraZeneca

Press Releases - No new digest announcements identified

Bharat Biotech, India

Press Releases - Website not responding at inquiry

BioCubaFarma – Cuba

Últimas Noticias

Más de 1 millón 115 mil cubanos ya han recibido al menos una dosis de los candidatos vacunales cubanos

24/05/2021 10:57:58 | Redacción de Cubadebate

[Google translate: More than 1,115,000 Cubans have already received at least one dose of the Cuban Soberana 02 vaccine candidates.]

"Cuba será posiblemente el primer país en vacunar a toda su población con una vacuna propia"

24/05/2021 10:47:43 | Redacción Cubadebate

[Google translate: "Cuba will possibly be the first country to vaccinate its entire population with its own vaccine"]

Más de 440 000 personas han sido vacunadas en Cuba como parte de la intervención sanitaria

24/05/2021 10:40:58 | Redacción de Cubadebate

[Google translate: More than 440,000 people have been vaccinated in Cuba as part of the health intervention]

CanSinoBIO

News - No new digest announcements identified

Clover Biopharmaceuticals - China

News - No new digest announcements identified

Curevac [Bayer Ag – Germany]

News

May 28, 2021

CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation

Gamaleya National Center

Latest News and Events - No new digest announcements identified *[See Russia/RFID below]*

IMBCAMS, China

Home - No new digest announcements identified

Janssen/JNJ

Press Releases - No new digest announcements identified

Moderna

Press Releases

May 25, 2021

Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June

:: Primary endpoint of non-inferior immunogenicity versus the Phase 3 study adult comparator group was met

:: No cases of COVID-19 observed after two doses of vaccine using the primary case definition, consistent with a vaccine efficacy of 100%

:: Safety and tolerability generally consistent with Phase 3 COVE study in adults; no significant safety concerns identified

:: Company plans to submit data to regulators globally in early June

May 24, 2021

Moderna and Aldevron Announce Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline

:: Aldevron will supply plasmid DNA to serve as the genetic template for generating the COVID-19 mRNA vaccine and other investigational programs in Moderna's pipeline.

Novavax

Press Releases

Novavax to Present at International Society for Vaccines Virtual Congress COVID-19 Vaccine Update 5/24/2021

Pfizer

Recent Press Releases

Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents

NEW YORK and MAINZ, GERMANY, May 28, 2021 — Pfizer Inc.(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the Conditional Marketing Authorization (CMA) for COMIRNATY® in the European Union (EU) has been expanded to include individuals 12 to 15 years of age. This follows the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion to authorize the vaccine in this age group. The extended indication for the CMA for COMIRNATY is valid in all 27 EU member states.

COMIRNATY was the first COVID-19 vaccine to receive authorization in the EU and is the first to have its CMA extended to adolescents. Distribution and administration of COMIRNATY by the EU member states will continue to be determined according to the populations identified in the EU and per national guidance...

Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults

Monday, May 24, 2021

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the first enrolled subjects have received their immunizations as part of a new study in adults ages 65 or older exploring the coadministration of the company's 20-valent pneumococcal conjugate vaccine (20vPnC) candidate following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine, currently authorized by the Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA). The primary objective in the trial is to describe safety when both vaccines are co-administered, with follow up six months after vaccination. Secondary objectives are to describe immune responses produced by each of the vaccines.

The trial will include 600 adults who will be recruited from the pivotal Phase 3 Pfizer-BioNTech COVID-19 Vaccine trial and will have received their second dose of the vaccine at least six months prior to entering the coadministration study. The participants are being randomized to one of three groups:

:: 20vPnC plus Pfizer-BioNTech COVID-19 Vaccine booster, which is a third dose of the Pfizer-BioNTech COVID-19 Vaccine

:: 20vPnC plus placebo

:: Pfizer-BioNTech COVID-19 Vaccine booster plus placebo

Serum Institute of India

NEWS & ANNOUNCEMENTS - No corporate announcements identified [Last release April 21.2021]

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases - No new digest announcements identified

Vector State Research Centre of Virology and Biotechnology

Home - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....

.....

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 29 May 2021

An overview of information collected from publicly announced bilateral and multilateral supply agreements [Agreements view from 2021-05-02 to date]



17

vaccines **approved for use** by at least one national regulatory authority ¹



5

vaccines in WHO's **Emergency Use Listing**



13.1bn

doses **secured globally**



\$1 - \$40

reported vaccine **price range** per dose



3.86bn

doses **secured & optioned** through COVAX ²



76.3M

doses **shipped through COVAX** to 126 countries

Deal date	Recipient	Deal type	Vaccine name	Vaccine developer	Manufacturer
5/3/2021	India	Bilateral	Serum Institute of India		Serum Institute of India
5/3/2021	India	Bilateral	Serum Institute of India		Serum Institute of India
5/4/2021	El Salvador	Bilateral	Pfizer BioNTech		Pfizer/BioNTech
5/5/2021	Peru	Bilateral	Pfizer BioNTech		Pfizer/BioNTech
5/6/2021	Brazil	Bilateral	Pfizer BioNTech		Pfizer/BioNTech
5/6/2021	COVAX	Multilateral	Novavax		Novavax
5/6/2021	Switzerland	Bilateral	Moderna		Moderna
5/10/2021	Peru	Bilateral	Beijing Institute of Biological Products (CNBG)		Beijing Institute of Biological Products (CNBG)
5/11/2021	Bolivia	Bilateral	Janssen Pharmaceuticals		Biolysse Pharma
5/12/2021	Australia	Bilateral	Moderna		Moderna
5/12/2021	Cambodia	Bilateral	Sinovac		Sinovac
5/13/2021	Bolivia	Bilateral	Beijing Institute of Biological Products (CNBG)		Beijing Institute of Biological Products (CNBG)
5/14/2021	Japan	Bilateral	Pfizer BioNTech		Pfizer/BioNTech
5/14/2021	Philippines	Bilateral	Pfizer BioNTech		Pfizer/BioNTech
5/14/2021	Viet Nam	Bilateral	Pfizer BioNTech		Pfizer/BioNTech
5/18/2021	Bangladesh	Bilateral	Beijing Institute of Biological Products (CNBG)		Beijing Institute of Biological Products (CNBG)

.....
.....

Our World in Data


Coronavirus (COVID-19) Vaccinations

Daily COVID-19 vaccine doses administered per 100 people, May 28, 2021

Our World in Data

Shown is the rolling 7-day average per 100 people in the total population. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).

[LINEAR](#) [LOG](#) [+ Add country](#)



Source: Official data collated by Our World in Data - Last updated 29 May, 13:00 (London time)
OurWorldInData.org/coronavirus • CC BY


► Dec 15, 2020 ○ May 28, 2021

Share of the population fully vaccinated against COVID-19, May 28, 2021

Our World in Data

Share of the total population that have received all doses prescribed by the vaccination protocol. This data is only available for countries which report the breakdown of doses administered by first and second doses.

[+ Add country](#)



Source: Official data collated by Our World in Data - Last updated 29 May, 13:00 (London time)
OurWorldInData.org/coronavirus • CC BY

► Dec 27, 2020 ○ May 28, 2021

.....
.....

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Vaccines and Related Biological Products Advisory Committee

:: [Vaccines and Related Biological Products Advisory Committee June 10, 2021 Meeting Announcement](#)

.....

White House [U.S.]

Briefing Room – Selected Major COVID Announcements

[Remarks by President Biden Celebrating the Significant Progress Virginia Has Made in the Fight Against COVID-19](#)

May 28, 2021 • Speeches and Remarks

[Statement by President Joe Biden on the Investigation into the Origins of COVID-19](#)

May 26, 2021 • Statements and Releases

...As of today, the U.S. Intelligence Community has “coalesced around two likely scenarios” but has not reached a definitive conclusion on this question. Here is their current position: “while two elements in the IC leans toward the former scenario and one leans more toward the latter – each with low or moderate confidence – the majority of elements do not believe there is sufficient information to assess one to be more likely than the other.”

I have now asked the Intelligence Community to redouble their efforts to collect and analyze information that could bring us closer to a definitive conclusion, and to report back to me in 90 days. As part of that report, I have asked for areas of further inquiry that may be required, including specific questions for China. I have also asked that this effort include work by our National Labs and other agencies of our government to augment the Intelligence Community’s efforts. And I have asked the Intelligence Community to keep Congress fully apprised of its work...

[Press Briefing by White House COVID-19 Response Team and Public Health Officials](#)

May 25, 2021 • Press Briefings

.....

COVID Data Tracker [U.S.] May 8, 2021

Total Vaccine Doses		People Vaccinated	At Least One Dose	Fully Vaccinated
Delivered	366,314,625	Total	167,157,043	134,418,748
Administered	293,705,050	% of Total Population	50.3%	40.5%
Learn more about the distribution of vaccines.		Population ≥ 12 Years of Age	167,033,116	134,410,002
		% of Population ≥ 12 Years of Age	59.6%	48%
		Population ≥ 18 Years of Age	161,086,059	132,216,482
		% of Population ≥ 18 Years of Age	62.4%	51.2%
		Population ≥ 65 Years of Age	46,931,392	40,828,394
		% of Population ≥ 65 Years of Age	85.8%	74.6%

About these data

CDC | Data as of: May 29, 2021 6:00am ET. Posted: Saturday, May 29, 2021 1:55 PM ET

.....
.....

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

[News & Press Releases](#) •

[News: First COVID-19 vaccine approved for children aged 12 to 15 in EU \(new\)](#)

CHMP, Last updated: 28/05/2021

EMA's human medicines committee (CHMP) has recommended granting an extension of indication for the COVID-19 vaccine Comirnaty to include use in children aged 12 to 15. The vaccine is already approved for use in adults and adolescents aged 16 and above.

...The use of the Comirnaty vaccine in children from 12 to 15 will be the same as it is in people aged 16 and above. It is given as two injections in the muscles of the upper arm, given three weeks apart.

The effects of Comirnaty in children were investigated in 2,260 children aged 12 to 15 years. This study was carried out in accordance with Comirnaty's paediatric investigation plan (PIP), which was agreed by EMA's Paediatric Committee (PDCO)...

[News: Insufficient data on use of inhaled corticosteroids to treat COVID-19 \(new\)](#)

Last updated: 27/05/2021

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

Latest Updates

[SARS-CoV-2 variants dashboard](#)

European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

News

Press release 28 May 2021

[The European Union outlines a €3 billion economic support package to a future democratic Belarus](#)

Today, the European Commission is presenting to the Council its outline for a comprehensive plan of economic support to a future democratic Belarus. The plan, of up to €3 billion, reflects the European Union's commitment to support the Belarusian people's wishes for a peaceful democratic transition.

Press release 27 May 2021

[Ukraine: EU allocates €25.4 million in humanitarian aid](#)

As the conflict in eastern Ukraine enters its eighth year, the European Commission has announced €25.4 million in humanitarian aid to help people still suffering from the ongoing hostilities.

Press release 25 May 2021

[EU increases humanitarian assistance for Palestine to over €34 million](#)

Today, the EU has increased its humanitarian assistance to the most vulnerable people in Palestine by €8 million, taking the total to €34.4 million this year.

.....
.....

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment

[Kenya's Statement on the Africa CDC Trusted Travels Platform](#)

25 May 2021

... I am particularly proud that Kenya was the pioneer country in the deployment of the Trusted Travel Platform, and this week also became the pioneer country to digitize vaccine data records in a manner that is compatible with the Trusted Vaccines Framework. These are unified digital platforms built and sustained through a public-private partnership among the AU institutions, on the one hand, and the Continental private sector, with support from Civil Society...

Press Releases

[Multi-Sectoral Task Force on Trusted Travel and Safe Re-Opening of Borders to foster Saving Lives, Economies, and Livelihoods on the African Continent](#)

Addis Ababa 24 May 2021 – African Ministers responsible for Health, ICT, and Transport have made a call to the African States to work towards harmonizing pre-entry and exit requirements for cross-border travel, increase mutual recognition, and cross-border information exchange. The Africa CDC, the lead COVID-19 response organ of the African Union, has gone further to provide a platform to member states to support this undertaking known as Trusted Travel (www.africacdc.org/trusted-travel). The Ministers also called for cross-collaboration among different sectors and stakeholders. The Call to Action comes under the umbrella of Africa Against COVID-19: "Saving Lives, Economies, and Livelihoods" campaign, which recognizes the need to define our "new normal" by striking a balance between saving lives, re-opening of economies, and revitalizing livelihoods within the African continent..

.....
.....

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

RDIF and UNICEF sign Sputnik V vaccine supply agreement

Moscow, May 27, 2021 – Human Vaccine LLC, a wholly owned subsidiary of the Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces the signing of an agreement for the supply of 220 million doses of two-dose Sputnik V Russian COVID-19 vaccine with the United Nations International Children's Emergency Fund (UNICEF). This amount is sufficient to vaccinate 110 million people.

The supply agreement with UNICEF for Sputnik V vaccine will broaden access to help meet vaccine demand around the world. Procurement and delivery of the vaccine by UNICEF is subject to the vaccine receiving WHO Emergency Use Listing. The decision is expected soon on the Sputnik V application for WHO Emergency Use Listing that was submitted in October 2020.

Concurrently, RDIF will be holding a separate discussion with Gavi, the Vaccine Alliance to see the Sputnik V vaccine considered for inclusion in the COVAX Facility's Portfolio of COVID-19 vaccines...

[See UNICEF announcement just below]

A study in Argentina confirms Sputnik V highly-effective against Manaus variant of coronavirus

Press release, 24.05.2021

RDIF and Panacea Biotec launch the production of Sputnik V in India

Press release, 24.05.2021

...The first batch produced at Panacea Biotec's facilities at Baddi will be shipped to the Gamaleya Center for quality control. Full-scale production of the vaccine is due to start this summer. Company's facilities comply with GMP standards and are prequalified by WHO.

Sputnik V was registered in India under the emergency use authorization procedure on April 12, 2021 and vaccination against coronavirus with the Russian vaccine started on May 14. As announced in April, RDIF and Panacea have agreed to produce 100 million doses per year of Sputnik V...

.....

UNICEF signs supply agreement for Sputnik V COVID-19 vaccine

News note 27 May 2021

NEW YORK/COPENHAGEN, 27 May 2021 - UNICEF and Human Vaccine (Limited Liability Company), a wholly-owned subsidiary of the Russian Direct Investment Fund (RDIF), today announced a long-term agreement (LTA) for the supply of the Sputnik V COVID-19 vaccine. This is the fourth long-term supply agreement UNICEF has signed with a COVID-19 vaccine manufacturer. So far this year, UNICEF has signed such agreements with the Serum Institute of India, Pfizer and AstraZeneca.

Procurement by UNICEF under this agreement is conditional on the product achieving an Emergency Use Listing from WHO, to confirm the quality, safety and efficacy of the vaccine.

In addition, an Advance Purchase Agreement (APA) with Gavi, the Vaccine Alliance, will also be needed for procurement to begin on behalf of the COVAX Facility. Should the COVAX Facility decide to enter into an advance purchase agreement for the supply of the Sputnik V vaccine, UNICEF will be ready to deliver as soon as regulatory milestones have been met. At this point, UNICEF through this LTA, stands ready to access up to 220 million doses of the vaccine available for supply in 2021, to

meet country demand. The Sputnik V vaccine consists of two different components of the vaccine to be administered 21 days apart. An exact delivery schedule will be determined in collaboration with the manufacturer...

.....
.....

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
29 May 2021, 08:00 IST
(GMT+5:30)

(↑↓ Status change since
yesterday)

Active (8.04%)

2228724 (114428↓)

Discharged (90.80%)

25178011 (284601↑)

Deaths (1.16%)

322512 (3617↑)

COVID-19 Vaccination
as on : 29 May 2021,
08:00 IST (GMT+5:30)

Total Vaccination : 20,89,02,445 (30,62,747 ↑)

27.05.2021

[Guidelines on near to Home COVID Vaccination Centres for Elderly & Differently Abled Citizens](#)

Government of India – Press Information Bureau

Latest Press Releases

[PM CARES For Children- Empowerment of COVID Affected Children launched for support & empowerment of Covid affected children](#)

Posted on: 29 May 2021

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

No new digest content identified.

.....
.....

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[See China CDC section below]

.....
.....
.....

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

Polio this week as of 26 May 2021

:: Come and join the virtual launch of the Polio Eradication Strategy 2022-2026, at an online event on Thursday 10 June 2021 (at 2pm, Central European Summer Time). More information, including registration details, are available [here](#), where you will find the 'Save the Date'.

:: Understanding gender-related barriers to immunization is essential to achieve polio eradication. But what is gender? What is the difference between gender and sex? How do sex and gender influence health, including immunization? [This newly released Q&A](#) examines the links between gender and health, highlighting WHO's ongoing work to address gender-related barriers to healthcare, advance gender equality and the empowerment of women and girls in all their diversity, and achieve health for all.

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):

- :: Pakistan: one cVDPV2 positive environmental sample
- :: Burkina Faso: one cVDPV2 case
- :: Congo: one cVDPV2 case
- :: DR Congo: five cVDPV2 cases
- :: Guinea: one cVDPV2 case
- :: Liberia: two cVDPV2 positive environmental samples
- :: Madagascar: three cVDPV1 cases and one cVDPV1 positive environmental sample
- :: Mali: one cVDPV2 case
- :: Tajikistan: two cVDPV2 positive environmental samples

.....
.....

WHO/OCHA Emergencies

Editor's Note:

Continuing with this edition, we include information about the last apparent update evident on the WHO emergency country webpages, recognizing almost universal and significant interims since last update regardless of the level of the emergency listed.

WHO Grade 3 Emergencies [to 29 May 2021]

Democratic Republic of the Congo - No new digest announcements identified [Last apparent update: 3 May 2021]

Mozambique floods - No new digest announcements identified [Last apparent update: 3 November 2020]

Nigeria - No new digest announcements identified [Last apparent update: 29 Jun 2020]

Somalia - No new digest announcements identified [Last apparent update: 13 July 2020]

South Sudan - No new digest announcements identified [Last apparent update: 4 February 2020]

Syrian Arab Republic - No new digest announcements identified [Last apparent update: 24 October 2020]

Yemen - *No new digest announcements identified [Last apparent update: 30 June 2020]*

.....

WHO Grade 2 Emergencies [to 29 May 2021]

Afghanistan - *No new digest announcements identified [Last apparent update: 5 July 2020]*

Angola - *No new digest announcements identified [Last apparent update: 16 March 2021]*

Burundi - *No new digest announcements identified [Last apparent update: 04 July 2019]*

Burkina Faso - *No new digest announcements identified [Last apparent update: 21 mai 2021]*

Cameroon - *No new digest announcements identified [Last apparent update: 22 August 2019]*

Central African Republic - *No new digest announcements identified [Last apparent update: 12 June 2018]*

Ethiopia - *No new digest announcements identified [Last apparent update: 22 August 2019]*

Iran floods 2019 - *No new digest announcements identified [Last apparent update: 2 March 2020]*

Iraq - *No new digest announcements identified [Last apparent update: 12 May 2021]*

Libya - *No new digest announcements identified [Last apparent update: 7 October 2019]*

Malawi - *No new digest announcements identified [Last apparent update: 22 April 2021]*

Measles in Europe - *No new digest announcements identified [Last apparent update: 26-04-2021]*

MERS-CoV - *No new digest announcements identified [Last apparent update: 8 July 2019]*

Mozambique - *No new digest announcements identified [Last apparent update: 03 November 2020]*

Myanmar - *No new digest announcements identified [Last apparent update: 29 March 2021]*

Niger - *No new digest announcements identified [Last apparent update: 16 avril 2021]*

occupied Palestinian territory - *No new digest announcements identified [Last apparent update: 4 September 2019]*

HIV in Pakistan - *No new digest announcements identified [Last apparent update: 27 August 2019]*

Sao Tome and Principe Necrotizing Cellulitis (2017) - *No new digest announcements*

Sudan - *No new digest announcements identified [Last apparent update: 24 June 2020]*

Ukraine - *No new digest announcements identified [Last apparent update: 1 May 2019]*

Zimbabwe - *No new digest announcements identified [Last apparent update: 10 May 2019]*

.....

WHO Grade 1 Emergencies [to 29 May 2021]

Kenya

:: Urgent immunization response launched to tackle polio outbreak in 13 counties

21 May 2021

Chad - *No new digest announcements identified [Last apparent update: 30 June 2018]*

Djibouti - *No new digest announcements identified [Last apparent update: 25 novembre 2020]*

Mali - *No new digest announcements identified [Last apparent update: 3 May 2017]*

Namibia - viral hepatitis - *No new digest announcements identified [Last apparent update: 20 July 2018]*

Tanzania - *No new digest announcements identified [Last apparent update: 21 October 2019]*

.....

.....

UN OCHA – Current Emergencies

Current Corporate Emergencies

Ethiopia

Ethiopia - Tigray Region Humanitarian Update Situation Report, 20 May 2021

HIGHLIGHTS

- :: Humanitarian needs continue to be grave, exceeding to current capacities.
- :: While some areas were accessible, others remain hard to reach due to movement restrictions and ongoing conflict.
- :: An alarming number of cases of acute malnutrition among children has been reported.
- :: Only about 2 per cent of the targeted 720,000 school children have access to learning opportunities.
- :: About US\$200 million is needed to respond to humanitarian needs until the end of July.

.....

.....

WHO & Regional Offices [to 29 May 2021]

<https://www.who.int/>

29 May 2021

News release

Update from the Seventy-fourth World Health Assembly – 29 May 2021

28 May 2021

Statement

Statement by the Malaria Policy Advisory Group on the urgent need to address the high prevalence of pfhrp2/3 gene deletions in the Horn of Africa and beyond

28 May 2021

Departmental news

World Health Assembly adopts new resolution on malaria

28 May 2021

News release

Update from the Seventy-fourth World Health Assembly – 28 May 2021

28 May 2021

News release

WHO supports people quitting tobacco to reduce their risk of severe COVID-19

28 May 2021

Departmental news

Public notice and comment on new Global Validation Advisory Committee (GVAC) members

27 May 2021

Statement

The President of the Republic of Costa Rica and the Director-General of the World Health Organization call once again on all WHO Member States to actively support the COVID-19 Technology Access Pool (C-TAP)

27 May 2021

News release

[Update from the Seventy-fourth World Health Assembly – 27 May 2021](#)

27 May 2021

Statement

[COVAX Joint Statement: Call to action to equip COVAX to deliver 2 billion doses in 2021](#)

27 May 2021

Departmental news

[World Health Assembly adopts decision to recognize 30 January as World NTD Day](#)

26 May 2021

Departmental news

[Kangaroo mother care started immediately after birth critical for saving lives, new research shows](#)

26 May 2021

Statement

[COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety \(GACVS\) reviews cases of mild myocarditis reported with COVID-19 mRNA vaccines](#)

25 May 2021

Statement

[IOAC statement at the Seventy-fourth World Health Assembly, 25 May 2021](#)

24 May 2021

Departmental news

[World No Tobacco Day 2021 awards - the winners](#)

24 May 2021

News release

[WHO and Switzerland launch global BioHub for pathogen storage, sharing and analysis](#)

.....

[Weekly Epidemiological Record, Vol. 96, No. 21, pp. 173–196 28 May 2021](#)

:: Dracunculiasis eradication: global surveillance summary, 2020194

:: Monthly report on dracunculiasis cases, January-March 2021196

:: Elimination of Human African Trypanosomiasis as public health problem)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: [Inside Africa's drive to boost medicines and vaccine manufacturing](#) 27 May 2021

With COVID-19 vaccine supplies to Africa slowing down, the continent is working to boost its own manufacturing capacities for vaccines, medicines and vital health technologies.

WHO Region of the Americas PAHO

No new digest content identified

WHO South-East Asia Region SEARO

:: 23 May 2021 News release

As COVID-19 cases surge, WHO provides over 340 MT of essential supplies to countries in South-East Asia Region

WHO European Region EURO

:: WHO recognizes decades of service of Ukrainian researchers in radiation medicine 28-05-2021

:: The Beautiful Game: keeping spectators, players and communities safe 28-05-2021

:: World No Tobacco Day 2021: awards for tobacco control in the WHO European Region 26-05-2021

:: Using big data to inform health care: opportunities, challenges and considerations 26-05-2021

:: WHO/Europe launches a new Russian-language podcast on the hottest health topics 25-05-2021

WHO Eastern Mediterranean Region EMRO

:: Many countries in the Eastern Mediterranean Region lagging behind in vaccination efforts

Cairo, 26 May 2021 – Almost 6 months into 2021, the Eastern Mediterranean Region is still far from vaccinating 20% of each country's population, the initial goal that WHO had set for 2021. Only 2 out of 22 countries in the Region have administered at least 1 dose of vaccine to over 50% of their populations. Most of the other countries have...

WHO Western Pacific Region

No new digest content identified

.....

.....

CDC/ACIP [U.S.] [to 29 May 2021]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases, Announcements

No new digest content identified

.....

MMWR News Synopsis Friday, May 28, 2021

:: HIV Viral Load Monitoring Among Patients Receiving Antiretroviral Therapy — Eight Sub-Saharan Africa Countries, 2013–2018

:: Mask Use and Ventilation Improvements To Reduce COVID-19 Incidence in Elementary Schools — Georgia, November 16–December 11, 2020 (Early Release May 21, 2021)

:: COVID-19 Testing To Sustain In-Person Instruction and Extracurricular Activities in High Schools — Utah, November 2020–March 2021 (Early Release May 21, 2021)

.....

Coronavirus Disease 2019 (COVID-19)- CDC

Selected Resources

Approximately 90 announcements/reports/data summaries.

.....
.....

Africa CDC [to 29 May 2021]

<http://www.africacdc.org/>

News

Statement

[Kenya's Statement on the Africa CDC Trusted Travels Platform](#)

25 May 2021

Press Releases

[Multi-Sectoral Task Force on Trusted Travel and Safe Re-Opening of Borders to foster Saving Lives, Economies, and Livelihoods on the African Continent](#)

Addis Ababa 24 May 2021 a

.....
.....

China CDC

<http://www.chinacdc.cn/en/>

[CCDC Weekly - Weekly Reports: Current Volume \(3\)](#)

2021-05-28 / No. 22

PDF of this issue

No new digest content identified.

National Health Commission of the People's Republic of China [to 29 May 2021]

<http://en.nhc.gov.cn/>

News

[May 29: Daily briefing on novel coronavirus cases in China](#)

On May 28, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 16 new cases of confirmed infections.

[Xi's remarks on promoting global cooperation against COVID-19 pandemic](#)

Updated: 2021-05-28

Xinhua

National Medical Products Administration – PRC [to 29 May 2021]

<http://english.nmpa.gov.cn/news.html>

News

[Over 560 mln COVID-19 vaccine doses administered across China](#)

2021-05-28

More than 566.72 million doses of COVID-19 vaccines had been administered across China as of Wednesday, the National Health Commission said on May 27.

.....

.....

Organization Announcements

Editor's Note:

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group [to 29 May 2021]

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

News

No new digest content identified.

BARDA – U.S. Department of HHS [to 29 May 2021]

<https://www.phe.gov/about/barda/Pages/default.aspx>

News

No new digest content identified.

BMGF - Gates Foundation [to 29 May 2021]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 29 May 2021]

<https://www.gatesmri.org/>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

No new digest content identified.

CARB-X [to 29 May 2021]

<https://carb-x.org/>

News

05.27.2021 |

[CARB-X is funding SNIPR BIOME to develop a CRISPR-engineered drug to eradicate Escherichia coli \(E. coli\) bacteria in cancer patients to prevent deadly infections](#)

CARB-X is awarding SNIPR BIOME ApS, a CRISPR- and microbiome-biotechnology company in Copenhagen, Denmark, up to US \$3.9 million to develop an innovative new drug to prevent E. coli infections in cancer patients, which can be life-threatening. Under the award, SNIPR BIOME may be eligible for up to \$6.3 million in additional funds from CARB-X if the project achieves certain milestones, subject to available funds.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 29 May 2021]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: [NEW] ***Informed Consent: A Monthly Review – May 2021*** is now posted [here](#)

CEPI – Coalition for Epidemic Preparedness Innovations [to 29 May 2021]

<http://cepi.net/>

Latest News

[COVAX Joint Statement: Call to action to equip COVAX to deliver 2 billion doses in 2021](#)

Now more than ever, at the peak of the pandemic, we need ambitious, global solutions.

27 May 2021

[See COVID above for full text]

[CEPI funds expansion of “mix and match” vaccine study, led by Oxford University](#)

Expanded study will assess the use of mixed COVID-19 vaccine regimens, specifically to include the Moderna and Novavax vaccines

COVID-19

26 May 2021

[CEPI and SK bioscience expand partnership to advance multiple COVID-19 variant vaccines and scale-up manufacturing](#)

CEPI to provide up to US\$173.4 million of additional funding to SK bioscience for its COVID-19 vaccine programme.

24 May 2021

DARPA – Defense Advanced Research Projects Agency [to 29 May 2021]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 29 May 2021]

<https://dukeghic.org/>

[WEEKLY COVID VACCINE RESEARCH UPDATE](#)

Last dated update: FRIDAY, April 16, 2021

EDCTP [to 29 May 2021]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

No new digest content identified.

Emory Vaccine Center [to 29 May 2021]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 29 May 2021]

<http://www.euvaccine.eu/>

Latest News

No new digest content identified.

FDA [to 29 May 2021]

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm>

Press Announcements / Selected Details

[May 28, 2021 - Coronavirus \(COVID-19\) Update: May 28, 2021](#)

[May 26, 2021 - Coronavirus \(COVID-19\) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19](#)

[May 25, 2021 - Coronavirus \(COVID-19\) Update: May 25, 2021](#)

[See U.S. COVID Actions above for detail]

Fondation Merieux [to 29 May 2021]

<http://www.fondation-merieux.org/>

News, Events

Mérieux Foundation co-organized event

[8th Annual meeting of the Global Task Force on Cholera Control \(GTFCC\)](#)

June 8 - 10, 2021 - Virtual Event

Gavi [to 29 May 2021]

<https://www.gavi.org/>

News Releases

27 May 2021

[Call to action to equip COVAX to deliver 2 billion doses in 2021](#)

[See COVID above for full text]

GHIT Fund [to 29 May 2021]

<https://www.ghitfund.org/newsroom/press>

GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that

No new digest content identified.

Global Fund [to 29 May 2021]

<https://www.theglobalfund.org/en/news/>

News & Stories

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 29 May 2021]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 29 May 2021]

<http://www.hillemanlabs.org/>

Website not responding at inquiry

Human Vaccines Project [to 29 May 2021]

<http://www.humanvaccinesproject.org/media/press-releases/>

Less Antibody than Expected May be Enough To Knock Out SARS-CoV-2

Danny Altmann, Ph.D.

Professor of Immunology

Imperial College London

IAVI [to 29 May 2021]

<https://www.iavi.org/newsroom>

PRESS RELEASES/FEATURES

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICRC [to 29 May 2021]

<https://www.icrc.org/en/whats-new>

Selected News Releases, Statements, Reports

[DR Congo: The population of Goma flees a volcano's menace as a major humanitarian crisis looms](#)

28-05-2021 | *News release*

[5 years on, there has not been significant change: access to health care continues to be impeded](#)

Speech given by Mr Peter Maurer, President of the ICRC, in the the Side Event on Protection of Health Care of the United Nations protection of civilians in armed conflict week.
26-05-2021 | *Statement*

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 29 May 2021]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

Americas

Pandemic not over, as transmission increases and health systems are at risk of collapsing in the Americas, IFRC warns

Panama City/Geneva, 28 May – The International Federation of Red Cross and Red Crescent societies (IFRC) is warning that the pandemic is far from over in the Americas as cases continue to surge. The region has the highest incidence of COVID-19 cases pe ...

29 May 2021

Bangladesh, India

India/Bangladesh: Millions threatened as cyclone spells double trouble

Kuala Lumpur/Delhi/Dhaka, 25 May – Red Cross and Red Crescent teams are helping people stay safe in India and Bangladesh as a major cyclone threatens millions of people and devastating COVID-19 surges continue in both countries. While India has been fa ...

25 May 2021

Global

No-one is safe until everyone is safe – why we need a global response to COVID-19

Equitable vaccine distribution is a humanitarian imperative. There is a choice. The world of the next 10 years can be one of greater justice, abundance and dignity. Or it can be one of conflict, insecurity and poverty. We are at a turning point. ...

24 May 2021

Institut Pasteur [to 29 May 2021]

<https://www.pasteur.fr/en/press-area>

Press Info

No new digest content identified.

IOM / International Organization for Migration [to 29 May 2021]

<http://www.iom.int/press-room/press-releases>

News

COVID-19 Behind Unprecedented Changes in the Number of Migrants Moving Across East and Horn of Africa: IOM Report

2021-05-25 15:35

Nairobi – At least 300,000 migrants across the East and Horn of Africa have been affected by COVID-19 in 2020, according to the International Organization for Migration (IOM)'s annual flagship report on migration trends and population movements in the region, released this week... The highest concentration of displaced persons is in Shire, where 575,115 IDPs are residing in overcrowded collective shelters, including schools, within the host community and in open spaces. The majority are from Western and Northwestern Tigray. Other urban areas with high displacement concentrations included Adwa (188,910), Sheraro (165,223), and Mekele Zone (200,909)...

IRC International Rescue Committee [to 29 May 2021]

<http://www.rescue.org/press-release-index>

Media highlights [Selected]

No new digest content identified.

IVAC [to 29 May 2021]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 29 May 2021]

<http://www.ivi.int/>

Selected IVI News, Announcements, Events

No new digest content identified.

JEE Alliance [to 29 May 2021]

<https://www.jeealliance.org/>

Selected News and Events

No new digest content identified.

Johns Hopkins Center for Health Security [to 29 May 2021]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News

New Report: School Ventilation: A Vital Tool to Reduce COVID-19 Spread

May 26, 2021

Johns Hopkins Center for Health Security receives a grant from The Rockefeller Foundation to deliver COVID-19 Response Research as part of the Exemplars in Global Health program

May 25, 2021

MSF/Médecins Sans Frontières [to 29 May 2021]

<http://www.msf.org/>

Latest [Selected Announcements

Myanmar

All parties must ensure unimpeded access to healthcare in Myanmar

Press Release 28 May 2021

Attacks on medical care

Trauma continues long after the bombing stops in Gaza

Project Update 28 May 2021

National Academy of Medicine - USA [to 29 May 2021]

<https://nam.edu/programs/>

Selected News/Programs

News

Expert Papers from the National Academy of Medicine Identify Lessons Learned and Compelling Needs for Health Care Payers and Clinicians and Professional Societies after COVID-19

May 26, 2021

WASHINGTON – In response to the devastating impact of COVID-19 on the American health system, the National Academy of Medicine (NAM) has convened experts in 9 sectors of health, health care, and biomedical research to review how each sector responded to COVID-19, identify challenges encountered in combating the pandemic, and outline what opportunities exist to [...]

National Vaccine Program Office - U.S. HHS [to 29 May 2021]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 29 May 2021]

<http://www.nih.gov/news-events/news-releases>

News Releases

No new digest content identified.

UN OCHA Office for the Coordination of Humanitarian Affairs [to 29 May 2021]

<https://www.unocha.org/>

Press Releases

No new digest content identified.

PATH [to 29 May 2021]

<https://www.path.org/media-center/>

Press Releases

STANDARD G6PD Test receives regulatory approval by the Australian Therapeutic Goods Administration

May 25, 2021 by PATH

Point-of-care test critical to improving the treatment and elimination of relapsing malaria receives regulatory approval.

PATH congratulates SD BIOSENSOR for the regulatory approval by the Australian Therapeutic Goods Administration (TGA) on April 21, 2021, of their STANDARD™ G6PD Test. The STANDARD G6PD Test is the first point-of-care test for glucose-6-phosphate dehydrogenase (G6PD) deficiency that can support safe access to the currently available drugs that treat Plasmodium vivax malaria in both men and women. The recent approval by the TGA certifies that the test is appropriate for use in point-of-care settings and meets rigorous quality standards...

Sabin Vaccine Institute [to 29 May 2021]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

Sabin Vaccine Institute Names Richard Adegbola and Yacine Djibo to Board of Trustees

Tuesday, May 25, 2021

Washington, D.C. – The Sabin Vaccine Institute (Sabin) announced that Professor Richard Adegbola and Yacine Djibo have been elected to the Board of Trustees. Professor Adegbola is a microbiologist, public health advocate and professor in Lagos, Nigeria. Ms. Djibo is founder and executive director of Speak Up Africa, a policy and advocacy action tank promoting public health and development based in Dakar, Senegal...

UNAIDS [to 29 May 2021]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

25 May 2021

UNAIDS supports the Partnership for Accelerated COVID-19 Testing in Ghana

25 May 2021

How the LGBTI community is surviving the COVID-19 pandemic in Indonesia

UNDP United Nations Development Programme [to 29 May 2021]

<http://www.undp.org/content/undp/en/home/presscenter.html>

Latest from News Centre

No new digest content identified.

UNHCR Office of the United Nations High Commissioner for Refugees [to 29 May 2021]

<http://www.unhcr.org/en-us/media-centre.html>

Selected News Releases, Announcements

Older refugees at heightened risk of exclusion as COVID-19 continues to strike the Americas

26 May 2021

Statement: No-one is safe until everyone is safe - why we need a global response to COVID-19

24 May 2021

[See COVID above for detail]

UNICEF [to 29 May 2021]

<https://www.unicef.org/media/press-releases>

Selected Press Releases, Statements

Statement 05/27/2021

COVAX Joint Statement: Call to action to equip COVAX to deliver 2 billion doses in 2021

[See COVID above for detail]

News note 05/27/2021

UNICEF signs supply agreement for Sputnik V COVID-19 vaccine

[See COVID above for detail]

News note 05/25/2021

Geneva Palais Briefing Note on COVID-19 in South Asia

[See COVID above for detail]

Statement 05/24/2021

No-one is safe until everyone is safe – why we need a global response to COVID-19

[See COVID above for detail]

Unitaid [to 29 May 2021]

<https://unitaid.org/>

Featured News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 29 May 2021]

<https://vaccineacceptance.org/>

Announcements

No new digest content identified.

Vaccine Confidence Project [to 29 May 2021]

<http://www.vaccineconfidence.org/>

News, Research and Reports

Coronavirus global impact

Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

Vaccine Education Center – Children’s Hospital of Philadelphia [to 29 May 2021]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

Vaccine Update for Providers

May 25, 2021

Announcements: Updated and new COVID-19 resources; essay contest deadline approaching

Wellcome Trust [to 29 May 2021]

<https://wellcome.ac.uk/news>

News and reports

No new digest content identified.

The Wistar Institute [to 29 May 2021]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 29 May 2021]

<https://www.wfpha.org/>

Latest News

WFPHA at WHA74: WFPHA Diplomats of the Global Charter for the Public’s Health: A Call for Pandemic Preparedness

May 28, 2021

WFPHA at WHA74: A Pandemic Treaty to Fight Inequalities & Health Emergencies

May 26, 2021

World Bank [to 29 May 2021]

<http://www.worldbank.org/en/news/all>

Selected News, Announcements

Jordan: The World Bank Group Adapts its Strategy to Support COVID-19 Response, Inclusive and Resilient Recovery, and Continued Reforms

The World Bank Group Board of Executive Directors Approves the Performance and Learning Review of the Country Partnership Framework for the Hashemite Kingdom of Jordan AMMAN, May 29, 2021 – Approved today...

Date: May 29, 2021 Type: Press Release

New \$30 million Grant to Support Palestinian Reforms in Digital Economy, Governance and Pandemic resilience

WASHINGTON, May 28, 2021 –The World Bank approved today a US\$30 million Development Policy Grant (DPG) to support the digital foundations of the Palestinian economy, strengthen recovery and resilience...

Date: May 28, 2021 Type: Press Release

World Customs Organization – WCO [to 29 May 2021]

<http://www.wcoomd.org/>

Latest News – Selected Items

28 May 2021

[The WCO Secretariat Note on the cross-border movement of vaccines enhanced with further guidance and good practices](#)

[See COVID above for detail]

World Organisation for Animal Health (OIE) [to 29 May 2021]

<https://www.oie.int/en/for-the-media/press-releases/2021/>

Press Releases

News

[New official disease status recognised by the World Organisation for Animal Health \(OIE\)](#)

27 May 2021

Two countries were the first to receive the endorsement of their dog-mediated rabies control programmes and 13 new official disease status were recognised by OIE Delegates... Having gathered evidence that their official control programmes comply with OIE international Standards, Namibia and the Philippines will be able to advocate for support from their governments to progressively prevent and control the disease. The ultimate objective will be to eventually eliminate the disease from their territories and self-declare its freedom, thus contributing to the '[Zero by 30](#)' global goal to eliminate human deaths from dog-mediated rabies...

News

[A new strategy propels international community to improve aquatic animal health and welfare worldwide](#)

26 May 2021

The World Organisation for Animal Health (OIE) is a leader in animal disease reporting. The recent innovation of the World Animal Health Information System (OIE-WAHIS) system is a testimony to the OIE's progressive evolution of its digital services. The platform provides Members with a new tool for animal disease surveillance for strengthened risk analysis and the monitoring during disease emergencies...

[Striving for One Health resilience](#)

25 May 2021

The World Organisation for Animal Health (OIE) is using lessons learned to re-envision its role, and that of its Members, on wildlife health, emergency management and sustainable laboratories. A specific Resolution addressing global vulnerabilities identified before and during the COVID-19 era in these domains will be proposed for adoption with the aim to better prepare against future health threats.

WTO - World Trade Organisation [to 29 May 2021]

http://www.wto.org/english/news_e/news_e.htm

WTO News and Events

[Webinar to explore role of regulatory cooperation in easing access to medical technologies](#)

28 May 2021

On 2 June 2021, a panel of experts will discuss regulatory cooperation and its role in facilitating access to medical technologies, especially in the context of the COVID-19 pandemic.

Goods barometer reveals strength of trade recovery, depth of COVID-19 shock

28 May 2021

Global merchandise trade is continuing to recover in 2021 following a steep but brief pandemic-induced drop in the second quarter of last year, according to the latest WTO Goods Trade Barometer released on 28 May.

.....

ARM [Alliance for Regenerative Medicine] [to 29 May 2021]

Press Releases - Alliance for Regenerative Medicine (alliancerm.org)

Selected Press Releases

Alliance for Regenerative Medicine, European Federation of Pharmaceutical Industries and Associations, and European Association for Bioindustries Call for Advanced Therapies to be Exempt from EU GMO Legislation

May 25, 2021

BIO [to 29 May 2021]

<https://www.bio.org/press-releases>

Press Releases

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 29 May 2021]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 29 May 2021]

<https://internationalbiotech.org/news/>

News

EU Healthcare Biotech Policy Priorities for SMEs

3 JUN. 2021 -- 03 Jun. 2021

Join the EuropaBio Healthcare Biotechnology Team for a dive into EU policies that impact your current operations and will shape your future strategies. With EU-level strategies within Pharmaceuticals, Intellectual Property, Orphan Medicines and the proposed 'European Health Emergency Preparedness and Response Authority (HERA)'...

IFPMA [to 29 May 2021]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

Global biopharmaceutical industry sees upcoming World Health Assembly as a critical milestone to take stock

24 May 2021, Geneva – The 74th World Health Assembly, taking place in extraordinary circumstances, represents a critical milestone in analyzing the world's response to the COVID-19 pandemic. Member States will engage in conversations on improving current systems for pandemic surveillance and response, against the backdrop of having multiple effective, safe and quality COVID-19 vaccines available.

Since the last World Health Assembly, innovative vaccine manufacturers and biotech companies – from both developed and developing countries – have broken records in drug innovation and collaboration.

In a matter of months, they have developed multiple COVID-19 vaccines, and have forged collaborations in order to ramp up production.

With nearly 300 partnerships and collaborations among manufacturers worldwide, production has increased, in just a few months from zero to 2.2 billion COVID-19 vaccine doses by the end of May, with an astounding estimate of 11 billion doses by the end of 2021[1].

Critically, however, COVID-19 vaccines currently are not equally reaching all priority populations worldwide. Innovative vaccine manufacturers and biotech companies committed last week to a five-step plan that will deliver results in the short-term...

PhRMA [to 29 May 2021]

<http://www.phrma.org/>

Selected Press Releases, Statements

A year later: Reflections on the meaning of equity

May 25, 2021

Over the past year, we have committed ourselves to this work, anew, through our Equity Initiative. *Courtney Christian* is a Senior Director of Policy and Research at PhRMA/

*

*

*

*

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 12, 2020 Issue 2

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 23, Number 5: E371-433 May 2021

<https://journalofethics.ama-assn.org/issue/ending-hiv-epidemic>

Ending the HIV Epidemic

A human immunodeficiency virus (HIV) epidemic began in the United States in the 1970s. "Ending the HIV Epidemic: A Plan for America" was launched in October 2019 by the US Department of Health and Human Services, with the goal of stopping the spread of HIV by 2030. Accomplishing this goal demands not only expanding existing programs, but recognizing and responding to clinically, ethically, socially, and culturally relevant features of contemporary patients' experiences of stigma, oppression, and living with HIV. This issue considers ethical and clinical complexities patients and clinicians encounter in HIV care today.

American Journal of Infection Control

May 2021 Volume 49 Issue 5 p533-656

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

May 2021 Volume 60 Issue 5 p595-736

<http://www.ajpmonline.org/current>

Research Articles

[Reviewed earlier]

American Journal of Public Health

May 2021 111(5)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 104 (2021): Issue 4 (Apr 2021)

<https://www.ajtmh.org/view/journals/tpmd/104/4/tpmd.104.issue-4.xml>

[Reviewed earlier]

Annals of Internal Medicine

May 2021 Volume 174, Issue 5

<http://annals.org/aim/issue>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 295 June 2021

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/295/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 29 May 2021)

[No new digest content identified]

BMJ Global Health

May 2021 - Volume 6 - Suppl 2

https://gh.bmj.com/content/6/Suppl_2

The future of vaccine safety

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 29 May 2021)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 29 May 2021)

[Modes of transmission of SARS-CoV-2 and evidence for preventive behavioral interventions](#)

COVID-19 is a novel disease caused by SARS-CoV-2. During the global vaccination rollout, it is vital to thoroughly understand the modes of transmission of the virus in order to prevent further spread of varian...

Authors: Lucas Zhou, Samuel K. Ayeh, Vignesh Chidambaram and Petros C. Karakousis

Citation: BMC Infectious Diseases 2021 21:496

Content type: Review

Published on: 28 May 2021

[Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis](#)

Favipiravir possesses high utility for treating patients with COVID-19. However, research examining the efficacy and safety of favipiravir for patients with COVID-19 is limited.

Authors: Toshie Manabe, Dan Kambayashi, Hiroyasu Akatsu and Koichiro Kudo

Citation: BMC Infectious Diseases 2021 21:489

Content type: Research article

Published on: 27 May 2021

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 29 May 2021)

[Stakeholders' perspectives on research integrity training practices: a qualitative study](#)

Even though research integrity (RI) training programs have been developed in the last decades, it is argued that current training practices are not always able to increase RI-related awareness within the scien...

Authors: Daniel Pizzolato and Kris Dierickx

Citation: BMC Medical Ethics 2021 22:67

Content type: Research article

Published on: 28 May 2021

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 29 May 2021)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 29 May 2021)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 29 May 2021)

[Intention to receive a COVID-19 vaccine: results from a population-based survey in Canada](#)

The success of any COVID-19 vaccine program ultimately depends on high vaccine uptake. This study determined overall intention to receive a COVID-19 vaccine and identified factors that predict intentions to be...

Authors: Gina S. Ogilvie, Shanlea Gordon, Laurie W. Smith, Arianne Albert, C. Sarai Racey, Amy Booth, Anna Gottschlich, David Goldfarb, Melanie C. M. Murray, Liisa A. M. Galea, Angela Kaida, Lori A. Brotto and Manish Sadarangani

Citation: BMC Public Health 2021 21:1017

Content type: Research

Published on: 29 May 2021

[Attitudes of Lebanese adults regarding COVID-19 vaccination](#)

COVID-19 was first detected in Lebanon on February 21, 2020; it reached its peak in January 2021, with a total number of 418,448 confirmed cases and 5380 deaths (until March 15, 2021). Gaining insight into fac...

Authors: Carina Kasrine Al Halabi, Sahar Obeid, Hala Sacre, Marwan Akel, Rabih Hallit, Pascale Salameh and Souheil Hallit

Citation: BMC Public Health 2021 21:998

Content type: Research

Published on: 27 May 2021

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>
(Accessed 29 May 2021)
[No new digest content identified]

BMJ Evidence-Based Medicine

June 2021 - Volume 26 - 3
<https://ebm.bmj.com/content/26/3>
[Reviewed earlier]

BMJ Open

May 2021 - Volume 11 - 5
<https://bmjopen.bmj.com/content/11/5>
[Reviewed earlier]

Bulletin of the World Health Organization

Volume 99, Number 5, May 2021, 321-404
<https://www.who.int/bulletin/volumes/99/5/en/>
[Reviewed earlier]

Cell

May 27, 2021 Volume 184 Issue 11 p2797-3074
<https://www.cell.com/cell/current>
[New issue; No digest content identified]

Child Care, Health and Development

Volume 47, Issue 3 Pages: 297-410 May 2021
<https://onlinelibrary.wiley.com/toc/13652214/current>
[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 109, Issue 5 Pages: 1159-1362 May 2021
<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>
[Reviewed earlier]

Clinical Therapeutics

Volume 43 Issue 3 p431-650, e57-e96
<http://www.clinicaltherapeutics.com/current>
[Reviewed earlier]

Clinical Trials

Volume 18 Issue 2, April 2021
<https://journals.sagepub.com/toc/ctja/18/2>
[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>
[Accessed 29 May 2021]
[No new digest content identified]

Contemporary Clinical Trials

Volume 103 April 2021
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/103/suppl/C>
[Reviewed earlier]

The CRISPR Journal

Volume 4, Issue 2 / April 2021
<https://www.liebertpub.com/toc/crispr/4/2>
[Reviewed earlier]

Current Genetic Medicine Reports

Volume 9, issue 2, June 2021
<https://link.springer.com/journal/40142/volumes-and-issues/9-2>
[Reviewed earlier]

Current Opinion in Infectious Diseases

June 2021 - Volume 34 - Issue 3
<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>
[Reviewed earlier]

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020
<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>
[Reviewed earlier]

Developing World Bioethics

Volume 21, Issue 1 Pages: i, 1-54 March 2021
<https://onlinelibrary.wiley.com/toc/14718847/current>
[Reviewed earlier]

Development in Practice

Volume 31, Issue 4, 2021
<http://www.tandfonline.com/toc/cdip20/current>
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 15 - Issue 1 - February 2021
<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>
[Reviewed earlier]

Disasters

Volume 45, Issue 2 Pages: 253-497 April 2021
<https://onlinelibrary.wiley.com/toc/14677717/current>
[Reviewed earlier]

EMBO Reports

Volume 22 Issue 5 5 May 2021
<https://www.embopress.org/toc/14693178/current>
[Reviewed earlier]

Emerging Infectious Diseases

Volume 27, Number 5—May 2021
<http://wwwnc.cdc.gov/eid/>
[Reviewed earlier]

Epidemics

Volume 34 March 2021
<https://www.sciencedirect.com/journal/epidemics/vol/34/suppl/C>
[Reviewed earlier]

Epidemiology and Infection

Volume 149 - 2021
<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>
[Reviewed earlier]

Ethics & Human Research

Volume 43, Issue 3 Pages: 1-44 May–June 2021
<https://onlinelibrary.wiley.com/toc/25782363/current>

Underrepresented populations in clinical research Human infection challenge trials
Articles

SARS-CoV-2 Human Challenge Trials: Rethinking the Recruitment of Healthy Young Adults First

Kenji Matsui, Yusuke Inoue, Keiichiro Yamamoto

Pages: 37-41

First Published: 06 April 2021

Commentary Free Access

Human Infection Challenge Experiments: Then and Now

Franklin G. Miller, Jonathan D. Moreno

Pages: 42-44

First Published: 15 March 2021

The European Journal of Public Health

Volume 31, Issue 2, April 2021

<https://academic.oup.com/eurpub/issue/31/2>

[Reviewed earlier]

Expert Review of Vaccines

Vol 20 (3) 2021

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 29 May 2021]

[No new digest content identified]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 29 May 2021]

Demonstrating trustworthiness when collecting and sharing genomic data: public views across 22 countries

Public trust is central to the collection of genomic and health data and the sustainability of genomic research. To merit trust, those involved in collecting and sharing data need to demonstrate they are trustworthy. However, it is unclear what measures are most likely to demonstrate this.

We analyse the 'Your DNA, Your Say' online survey of public perspectives on genomic data sharing including responses from 36,268 individuals across 22 low-, middle- and high-income countries, gathered in 15 languages. We examine how participants perceived the relative value of measures to demonstrate the trustworthiness of those using donated DNA and/or medical information. We examine between-country variation and present a consolidated ranking of measures.

Authors: Richard Milne, Katherine I. Morley, Mohamed A. Almarri, Shamim Anwer, Jerome Atutornu, Elena E. Baranova, Paul Bevan, Maria Cerezo, Yali Cong, Alessia Costa, Christine Critchley, Josepine Fernow, Peter Goodhand, Qurratulain Hasan, Aiko Hibino, Gry Houeland...

Citation: Genome Medicine 2021 13:92

Content type: Research
Published on: 25 May 2021

Global Health Action

Volume 14, Issue 1 (2021)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 9, No. 1 March 2021

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Public Health

Volume 16, Issue 6 (2021)

<http://www.tandfonline.com/toc/rgph20/current>

Special Symposium on Social Norms and Violence against Children

[New issue; No digest content identified]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 29 May 2021]

[No new digest content identified]

Health Affairs

Vol. 40, No. 5 May 2021

<https://www.healthaffairs.org/toc/hlthaff/current>

May 2021 / Consolidation, Private Equity & More

[New issue; No digest content identified]

Health and Human Rights

Volume 22, Issue 1, June 2020

<https://www.hhrjournal.org/volume-22-issue-1-june-2020/>

Special Section: Mental Health and Human Rights

[Reviewed earlier]

Health Economics, Policy and Law

Volume 16 - Issue 2 - April 2021

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 36, Issue 4, May 2021

<https://academic.oup.com/heapol/issue/36/4>

ORIGINAL ARTICLES

Socio-economic determinants of global COVID-19 mortalities: policy lessons for current and future pandemics

Nicholas Ngepah

Health Policy and Planning, Volume 36, Issue 4, May 2021, Pages 418–434,

<https://doi.org/10.1093/heapol/czaa161>

Impact of campaign-style delivery of routine vaccines: a quasi-experimental evaluation using routine health services data in India

Emma Clarke-Deelder, Christian Suharlim, Susmita Chatterjee, Logan Brenzel, Arindam Ray ...

Health Policy and Planning, Volume 36, Issue 4, May 2021, Pages 454–463,

<https://doi.org/10.1093/heapol/czab026>

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 29 May 2021]

[No new digest content identified]

Human Gene Therapy

Volume 32, Issue 9-10 / May 2021

<https://www.liebertpub.com/toc/hum/32/9-10>

[New issue; No digest content identified]

Humanitarian Exchange Magazine

Number 79, May 2021

<https://odihpn.org/magazine/inclusion-of-persons-with-disabilities-in-humanitarian-action-what-now/>

Localisation and local humanitarian action

by HPN October 2020

The theme of this edition of *Humanitarian Exchange* is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 17, Issue 5, 2021

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/content>

[Accessed 29 May 2021]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

[Accessed 29 May 2021]

[No new digest content identified]

International Health

Volume 13, Issue 3, May 2021

<https://academic.oup.com/inthealth/issue/13/3>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 8, No 5 (2021) May 2021

<https://www.ijcmph.com/index.php/ijcmph/issue/view/76>

[Reviewed earlier]

International Journal of Epidemiology

Volume 50, Issue 2, April 2021

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 14 Issue 1 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/1>

Table of Contents

[Reviewed earlier]

International Journal of Infectious Diseases

Volume 106 p1-430

<https://www.ijidonline.com/current>

[Reviewed earlier]

JAMA

May 25, 2021, Vol 325, No. 20, Pages 2031-2126

<https://jamanetwork.com/journals/jama/currentissue>

[New issue; No digest content identified]

JAMA Network

[COVID-19 Update May 29, 2021](#)

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics

May 2021, Vol 175, No. 5, Pages 449-544

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBİ Evidence Synthesis

May 2021 - Volume 19 - Issue 5

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

Volume 68 Issue 6 p1025-1222

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 71 (2021)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 46, issue 3, June 2021

<https://link.springer.com/journal/10900/volumes-and-issues/46-3>

[Reviewed earlier]

Journal of Development Economics

Volume 150 May 2021

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/150/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 16 Issue 1-2, February-April 2021

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

May 2021 - Volume 75 - 5

<https://jech.bmj.com/content/75/5>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 14, Issue 1 Pages: 1-81 February 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 16, Issue 3, 2020

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 32, Number 2, May 2021 Supplement

<https://muse.jhu.edu/issue/44396>

Table of Contents

Overview of the Issue

Kevin B. Johnson, Tiffani J. Bright, Cheryl R. Clark

...The importance of techquity—defined as the strategic development and deployment of technology in health care and health to advance health equity—was even more apparent after the events of 2020. COVID-19 upended access to care and illuminated the impact of structural racism as a cause for a widening gap of access during the pandemic. Black Lives Matter became more than a trending hashtag on Twitter, or a movement resulting in peaceful protests and calls for policy reform: it put additional focus on the issue of race as a social and not a biological construct and called into question the rationale for common practices in health care that were triggered by race. A notable example was the emerging realization that kidney function assessment was tied to race and hardwired into many of our electronic health records. The real-world evidence around our lack of techquity was incontrovertible.

This Supplemental Issue of JHCPU provides articles that describe challenges to techquity, frameworks to improve the role of technology in care, and examples of how technology can transform health, public health, and health care...

Journal of Immigrant and Minority Health

Volume 23, issue 3, June 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-3>
[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 19, 2021_ Issue 2

<https://www.tandfonline.com/toc/wimm20/current>
[Reviewed earlier]

Journal of Infectious Diseases

Volume 223, Issue 7, 1 April 2021

<https://academic.oup.com/jid/issue/223/7>
[Reviewed earlier]

Journal of Medical Ethics

May 2021 - Volume 47 - 5

<http://jme.bmj.com/content/current>
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 8, Issue 2 (2021)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>
[Reviewed earlier]

Journal of Pediatrics

Volume 233 p1-300

<http://www.jpeds.com/current>
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 29 May 2021]

[No new digest content identified]

Journal of Public Health Management & Practice

May/June 2021 - Volume 27 - Issue 3

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>
[Reviewed earlier]

Journal of Public Health Policy

Volume 42, issue 1, March 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-1>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

May 2021 Volume 18 Issue 178

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 28, Issue 3, April 2021

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

May 2021; Volume 95, Issue 10

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

May 29, 2021 Volume 397 Number 10289 p2023-2124

<https://www.thelancet.com/journals/lancet/issue/current>

[New issue; No digest content identified]

The Lancet Child & Adolescent Health

May 2021 Volume 5 Number 5 p309-384, e12-e18

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

May 2021 Volume 3 Number 5 e274-e329

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

May 2021 Volume 9 Number 5 e558-e720

<https://www.thelancet.com/journals/langlo/issue/current>
[Reviewed earlier]

Lancet Infectious Diseases

May 2021 Volume 21 Number 5 p579-742, e110-e140
<https://www.thelancet.com/journals/laninf/issue/current>
[Reviewed earlier]

Lancet Public Health

May 2021 Volume 6 Number 5 e260-e345
<https://www.thelancet.com/journals/lanpub/issue/current>
[Reviewed earlier]

Lancet Respiratory Medicine

May 2021 Volume 9 Number 5 p435-544, e47-e50
<https://www.thelancet.com/journals/lanres/issue/current>
[Reviewed earlier]

Maternal and Child Health Journal

Volume 25, issue 5, May 2021
<https://link.springer.com/journal/10995/volumes-and-issues/25-5>
[Reviewed earlier]

Medical Decision Making (MDM)

Volume 41 Issue 4, May 2021
<http://mdm.sagepub.com/content/current>
[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy
Volume 99, Issue 1 Pages: 1-327 March 2021
<https://onlinelibrary.wiley.com/toc/14680009/current>
[Reviewed earlier]

Nature

Volume 593 Issue 7860, 27 May 2021
<https://www.nature.com/nature/volumes/593/issues/7860>
Editorial | 26 May 2021

[Protect precious scientific collaboration from geopolitics](#)

Rivalry between China and other countries could diminish global scientific collaboration — just when it is most needed.

Editorial | 25 May 2021

[A patent waiver on COVID vaccines is right and fair](#)

Wealthier countries must join the United States, Russia and China in recognizing that everyone benefits if vaccine manufacturing is distributed evenly around the world.

World View | 26 May 2021

[Stem-cell guidelines: why it was time for an update](#)

New oversight criteria aim to reassure the public and permit progress in contentious research, such as growing human embryos in the lab.

Nature Biotechnology

Volume 39 Issue 5, May 2021

<https://www.nature.com/nbt/volumes/39/issues/5>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 29 May 2021)

[No new digest content identified]

Nature Genetics

Volume 53 Issue 5, May 2021

<https://www.nature.com/ng/volumes/53/issues/5>

[Reviewed earlier]

Nature Human Behaviour

Volume 5 Issue 5, May 2021

<https://www.nature.com/nathumbehav/volumes/5/issues/5>

[Reviewed earlier]

Nature Medicine

Volume 27 Issue 5, May 2021

<https://www.nature.com/nm/volumes/27/issues/5>

[Reviewed earlier]

Nature Reviews Genetics

Volume 22 Issue 5, May 2021

<https://www.nature.com/nrg/volumes/22/issues/5>

[Reviewed earlier]

Nature Reviews Immunology

Volume 21 Issue 5, May 2021

<https://www.nature.com/nri/volumes/21/issues/5>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 20 Issue 5, May 2021

<https://www.nature.com/nrd/volumes/20/issues/5>

[Reviewed earlier]

New England Journal of Medicine

May 27, 2021 Vol. 384 No. 21

<http://www.nejm.org/toc/nejm/medical-journal>

Perspective

The “Legal Epidemiology” of Pandemic Control

Scott Burris, J.D., Evan D. Anderson, J.D., Ph.D., and Alexander C. Wagenaar, M.S.W., Ph.D.

The centrality of law as a public health intervention has been undeniable during the Covid-19 pandemic. In just the first half of 2020, more than 1000 laws and orders were issued by federal, state, and local authorities in the United States in an effort to reduce disease transmission. Legal interventions include stay-at-home orders, mask mandates, and travel restrictions, as well as more particular rules for business operations, alcohol sales, curfews, and health care. Given their heavy use, importance, and obvious socioeconomic side effects, and the social and behavioral complexities of their implementation, one might have expected the National Institutes of Health (NIH), other research funders, and the research community to jump to the work of determining the right mix, intensity, and enforcement approaches of legal restrictions to control transmission with the least and most equitably distributed harms. No organized research program emerged...

Perspective

A Hidden Opportunity — Medicaid’s Role in Supporting Equitable Access to Clinical Trials

Samuel U. Takvorian, M.D., M.S.H.P., Carmen E. Guerra, M.D., M.S.C.E., and William L. Schpero, Ph.D.

Hidden deep within the \$2.3 trillion omnibus spending and relief package passed by Congress in December 2020 lies a little-known but powerful provision intended to promote equitable access to clinical trials. Beginning in January 2022, coverage of the “routine costs” associated with clinical trial participation will be guaranteed for all Medicaid beneficiaries for the first time in the program’s history. The absence of federal policy in this area until now has most likely suppressed the representation of low-income and minority populations in the clinical research that underlies therapeutic advances, thereby limiting equitable access to potentially state-of-the-art therapies and compromising the generalizability of research findings...

Pediatrics

Vol. 147, Issue 5 1 May 2021

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

PharmacoEconomics

Volume 39, issue 5, May 2021

<https://link.springer.com/journal/40273/volumes-and-issues/39-5>

[Reviewed earlier]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 29 May 2021)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 29 May 2021)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 29 May 2021)

[The impact of the COVID-19 pandemic on rabies reemergence in Latin America: The case of Arequipa, Peru](#)

Brinkley Raynor, Elvis W. Díaz, Julianna Shinnick, Edith Zegarra, Ynes Monroy, Claudia Mena, Micaela De la Puente-León, Michael Z. Levy, Ricardo Castillo-Neyra

Research Article | published 21 May 2021 PLOS Neglected Tropical Diseases

<https://doi.org/10.1371/journal.pntd.0009414>

PLoS One

<http://www.plosone.org/>

[Accessed 29 May 2021]

[Impact of influenza vaccination in the Netherlands, 2007–2016: Vaccinees consult their general practitioner for clinically diagnosed influenza, acute respiratory infections, and pneumonia more often than non-vaccinees](#)

Saverio Caini, John Paget, Peter Spreeuwenberg, Joke C. Korevaar, Adam Meijer, Mariëtte Hooiveld

Research Article | published 28 May 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0249883>

[Willingness to participate in COVID-19 vaccine trials; a survey among a population of healthcare workers in Uganda](#)

Jonathan Kitonsa, Onesmus Kamacooko, Ubaldo Mushabe Bahemuka, Freddie Kibengo, Ayoub Kakande, Anne Wajja, Vincent Basajja, Alfred Lumala, Edward Ssemwanga, Robert Asaba, Joseph Mugisha, Benjamin F. Pierce, Robin Shattock, Pontiano Kaleebu, Eugene Ruzagira

Research Article | published 27 May 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0251992>

Booster immunization of meningococcal meningitis vaccine among children in Hangzhou, China, 2014-2019

Xinren Che, Yan Liu, Jun Wang, Yuyang Xu, Xuechao Zhang, Wenwen Gu, Wei Jiang, Jian Du, Xiaoping Zhang

Research Article | published 25 May 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0251567>

Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults

Janeta Nikolovski, Martin Koldijk, Gerrit Jan Weverling, John Spertus, Mintu Turakhia, Leslie Saxon, Mike Gibson, John Whang, Troy Sarich, Robert Zambon, Nnamdi Ezeanochie, Jennifer Turgiss, Robyn Jones, Jeff Stoddard, Paul Burton, Ann Marie Navar

Research Article | published 24 May 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0251963>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 29 May 2021]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States of America

May 11, 2021; vol. 118 no. 19

<https://www.pnas.org/content/118/19>

Brief Reports *Open Access*

A megastudy of text-based nudges encouraging patients to get vaccinated at an upcoming doctor's appointment

Katherine L. Milkman, Mitesh S. Patel, Linnea Gandhi, Heather N. Graci, Dena M. Gromet, Hung Ho, Joseph S. Kay, Timothy W. Lee, Modupe Akinola, John Beshears, Jonathan E. Bogard, Alison Buttenheim, Christopher F. Chabris, Gretchen B. Chapman, James J. Choi, Hengchen Dai, Craig R. Fox, Amir Goren, Matthew D. Hilchey, Jillian Hmurovic, Leslie K. John, Dean Karlan, Melanie Kim, David Laibson, Cait Lambertson, Brigitte C. Madrian, Michelle N. Meyer, Maria Modanu, Jimin Nam, Todd Rogers, Renante Rondina, Silvia Saccardo, Maheen Shermohammed, Dilip Soman, Jehan Sparks, Caleb Warren, Megan Weber, Ron Berman, Chalanda N. Evans, Christopher K. Snider, Eli Tsukayama, Christophe Van den Bulte, Kevin G. Volpp, and Angela L. Duckworth

PNAS May 18, 2021 118 (20) e2101165118; <https://doi.org/10.1073/pnas.2101165118>

Prehospital & Disaster Medicine

Volume 36 - Issue 3 - June 2021

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 146 May 2021

<https://www.sciencedirect.com/journal/preventive-medicine/vol/146/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

26 May 2021 Volume 288 Issue 1951

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 193 Pages 1-156 (April 2021)

<https://www.sciencedirect.com/journal/public-health/vol/193/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 13, Issue 3, November 2020

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 136 Issue 3, May 2021

<https://journals.sagepub.com/toc/phrg/136/3>

[Reviewed earlier]

Qualitative Health Research

Volume 31 Issue 6, May 2021

<http://qhr.sagepub.com/content/current>

[Reviewed earlier]

Research Ethics

Volume 17 Issue 2, April 2021

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 29 May 2021]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Selected Articles

25 May 2021

Genomic surveillance of SARS-CoV-2 in response to the pandemic from COVID-19 in Brazil

Letter | Portuguese |

25 May 2021

Socioeconomic inequalities in HIV knowledge, HIV testing, and condom use among adolescent and young women in Latin America and the Caribbean

Original research | English |

25 May 2021

Analysis of implementation outcomes of quality improvement initiatives in Haiti: the fingerprint initiative

Original research | English |

25 May 2021

Antibiotic prophylaxis for surgical procedures: a scoping review

Review | English |

Risk Analysis

Volume 41, Issue 5 Pages: 701-841 May 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

Special Issue: Global Systemic Risk and Resilience for Novel Coronavirus and COVID-19: Part 1

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 29 May 2021]

[No new digest content identified]

Science

28 May 2021 Vol 372, Issue 6545

<http://www.sciencemag.org/current.dtl>

Feature

Doses of reality

By Jon Cohen

Science 28 May 2021 : 896-899 Full Access

The Serum Institute of India aimed to be a major world supplier of COVID-19 vaccines. India's pandemic got in the way.

Deadly delays

By Jon Cohen

Science 28 May 2021 : 900-902 Full Access

Unexpected vaccine hesitancy, dose shortages, and poor government planning have compounded India's massive immunization challenge.

Fairer shares

By Jon Cohen, Kai Kupferschmidt

Science 28 May 2021 : 903-906 Full Access

Rich countries cornered the marketplace for COVID-19 vaccines. Here are four strategies to protect the rest of the world.

Reports

Resurgence of SARS-CoV-2: Detection by community viral surveillance

By Steven Riley, Kylie E. C. Ainslie, Oliver Eales, Caroline E. Walters, Haowei Wang, Christina Atchison, Claudio Fronterre, Peter J. Diggle, Deborah Ashby, Christl A. Donnelly, Graham Cooke, Wendy Barclay, Helen Ward, Ara Darzi, Paul Elliott

Science 28 May 2021 : 990-995 Open Access

Representative community antigen sampling can improve situational awareness and help evaluate interventions at low SARS-CoV-2 prevalence.

Science Translational Medicine

26 May 2021 Vol 13, Issue 595

<https://stm.sciencemag.org/>

[New issue; No digest content identified]

Social Science & Medicine

Volume 276 May 2021

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/276/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 29 May 2021]

Evidence on collaboration of traditional and biomedical practitioners in the management of antimicrobial resistance in sub-Saharan Africa over 15 years: a systematic review protocol

The overuse of prescribed antimicrobials, concurrent use of traditional medicine, and prescribed antimicrobials have led to antimicrobial resistance. The absence of collaboration between traditional health pra...

Authors: Aganze Gloire-Aimé Mushebenge, Mukanda Gedeon Kadima, Tivani Mashamba-Thompson and Manimbulu Nlooto

Citation: Systematic Reviews 2021 10:158

Content type: Protocol

Published on: 28 May 2021

Theoretical Medicine and Bioethics

Volume 41, issue 5-6, December 2020

<https://link.springer.com/journal/11017/volumes-and-issues/41-5>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 41 May–June 2021

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/41/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 26, Issue 5 Pages: i-iv, 503-608 May 2021

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 39, Issue 21 Pages 2811-2906 (18 May 2021)

<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/21>

Discussion Full text access

[Ethics and execution of developing a 2nd wave COVID vaccine – Our interim phase I/II VSV-SARS-CoV2 vaccine experience](#)

Yotam Levin, Noa Madar Balakirski, Yoseph Caraco, Eytan Ben-Ami, ... Hadar Marcus

Pages 2821-2823

Research article Full text access

[Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: A national cross-sectional study](#)

Chao Wang, Bingfeng Han, Tianshuo Zhao, Hanyu Liu, ... Fuqiang Cui

Pages 2833-2842

Research article Abstract only

[The impact of paid family leave on the timely vaccination of infants](#)

Agnitra Roy Choudhury, Solomon W. Polachek

Pages 2886-2893

Research article Open access

[Incorporating equity in infectious disease modeling: Case study of a distributional impact framework for measles transmission](#)

Tigist Ferede Menkir, Abdulrahman Jbaily, Stéphane Verguet

Pages 2894-2900

Vaccines — Open Access Journal

<http://www.mdpi.com/journal/vaccines>

(Accessed 29 May 2021)

Open Access Article

Vaccine Production Process: How Much Does the General Population Know about This Topic? A Web-Based Survey

by Angela Bechini et al

Vaccines 2021, 9(6), 564; <https://doi.org/10.3390/vaccines9060564> (registering DOI) - 29 May 2021

Abstract

Background: Vaccine hesitancy has been recognized as a major global health threat by the World Health Organization. Many studies have investigated vaccine safety as a determinant for vaccine hesitancy; however, not much attention has been paid to vaccine production and quality control during [...]

Open Access Article

Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects

by Ma'mon M. Hatmal et al

Vaccines 2021, 9(6), 556; <https://doi.org/10.3390/vaccines9060556> - 26 May 2021

Abstract

Background: Since the coronavirus disease 2019 (COVID-19) was declared a pandemic, there was no doubt that vaccination is the ideal protocol to tackle it. Within a year, a few COVID-19 vaccines have been developed and authorized. This unparalleled initiative in developing vaccines created [...]

Open Access Article

Maternal Vaccination in Uganda: Exploring Pregnant Women, Community Leaders and Healthcare Workers' Perceptions

By Phiona Nalubega

Vaccines 2021, 9(6), 552; <https://doi.org/10.3390/vaccines9060552> - 25 May 2021

Abstract

Background: We investigated pregnant women, community leaders, healthcare workers (HCWs) and programme managers' perceptions of maternal vaccination in Kampala, Uganda. Methods: We conducted focus group discussions, key informant interviews and in-depth discussions with HCWs (3), community leaders (3), pregnant women (8) and programme [...]

Open Access Review

Factors Influencing Public Attitudes towards COVID-19 Vaccination: A Scoping Review Informed by the Socio-Ecological Model

by Ghadir Fakhri Al-Jayyousi

Vaccines 2021, 9(6), 548; <https://doi.org/10.3390/vaccines9060548> - 24 May 2021

Abstract

Major hindrances to getting a COVID-19 vaccine include vaccine hesitancy, skepticism, refusal, and anti-vaccine movements. Several studies have been conducted on attitudes of the public towards COVID-19 vaccines and the potential influencing factors. The purpose of this scoping review is to summarize the [...]

Value in Health

Volume 24 Issue 5 p605-752

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

* * * *

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

The sheer volume of vaccine and pandemic-related coverage is extraordinary. We will strive to present the most substantive analysis and commentary we encounter.

The Atlantic

<http://www.theatlantic.com/magazine/>

Accessed 29 May 2021

[No new, unique, relevant content]

BBC

<http://www.bbc.co.uk/>

Accessed 29 May 2021

[No new, unique, relevant content]

The Economist

<http://www.economist.com/>

Accessed 29 May 2021

[Possible, but far from proven - Assessing the theory that covid-19 leaked from a Chinese lab](#)

The evidence so far is circumstantial

May 29th 2021 edition

Financial Times

<https://www.ft.com/>

Accessed 29 May 2021

[Malaysia announces 'total lockdown' after surge in cases and deaths](#)

May 28, 2021

Covid-19 vaccines

WHO reboots IP sharing scheme for Covid shots, drugs and tests

May 27, 2021

Forbes

<http://www.forbes.com/>

Accessed 29 May 2021

May 29, 2021

Some Countries With The Highest Vaccination Rates Are Facing A Surge In Covid Deaths And Infections—Experts Say Complacency Is Partly To Blame

Countries with much higher vaccination rates than the U.S. are experiencing deadly outbreaks of Covid-19.

By Robert Hart Forbes Staff

May 28, 2021

Employers Can Require Workers To Get Vaccinated, Government Says

The Equal Employment Opportunity Commission also said employers can offer vaccine incentives to their workers, such as cash stipends.

By Jack Brewster Forbes Staff

Foreign Affairs

<http://www.foreignaffairs.com/>

Accessed 29 May 2021

Snapshot May 26, 2021

India's Cascading COVID-19 Failures

The staggering cost of an unscientific response to the pandemic.

Ramanan Laxminarayan

Foreign Policy

<http://foreignpolicy.com/>

Accessed 29 May 2021

Latin America's Vaccine Stars and Struggles

Technology transfers to produce shots are slowly underway in the region.

By Catherine Osborn May 21, 2021

New Yorker

<http://www.newyorker.com/>

Accessed 29 May 2021

Annals of Inquiry

The Sudden Rise of the Coronavirus Lab-Leak Theory

Scientists and political commentators are no longer dismissing the possibility that COVID-19 emerged from a Chinese laboratory. What changed?

By Benjamin Wallace-Wells

May 27, 2021

New York Times

<http://www.nytimes.com/>

Accessed 29 May 2021

Europe

Hundreds Protest Vaccine Passports in London

Demonstrators opposing coronavirus vaccines and the idea of vaccine passports gathered in central London on Saturday.

By The Associated Press and Reuters

May 29, 2021

Americas

'Like a Dream': Latin Americans Head to U.S. for Covid Shots

Frustrated with the lagging pace of vaccinations at home, well-off Latin Americans have been flying north for a shot — and feeling guilty about those left behind.

By Ernesto Londoño, Daniel Politi and Santi Carneri

May 29, 2021

U.S.

California to Give \$116.5 million to Vaccinated Residents

Gov. Gavin Newsom of California announced on Thursday a \$116.5 million giveaway to residents who have received a coronavirus vaccination in an effort to motivate people to get a shot.

Asia Pacific

Japan extends a state of emergency until one month before the Olympics.

With infections still high, restrictions in nine prefectures will remain in place until at least June 20, casting more doubt on the start of the Summer Games in Tokyo.

By Hisako Ueno and Motoko Rich

May 28, 2021

Opinion

Vaccinate the World! The Best Investment Ever.

Here's a way for Biden to assert United States leadership to benefit the world and safeguard the American economy.

By Nicholas Kristof

PRINT EDITION May 27, 2021, Page A18

Business

Influencers Say They Were Urged to Criticize Pfizer Vaccine

A disinformation effort to reduce public confidence in Covid-19 vaccines tried to enroll social media commentators in France and Germany.

By Liz Alderman

Opinion Guest Essay

This Is the Wrong Way to Distribute Badly Needed Vaccines

May 24, 2021

By Ezekiel J. Emanuel and Govind Persad

...But to be fair and successful, Covax must abandon its purely population-based distribution formula, developed by W.H.O., which has led to precious vaccine doses being destroyed or left sitting in freezers in countries without many cases or which lack the ability to distribute them effectively. Fair distribution of vaccines must be based primarily on need...

...Need should be the principal criterion for distributing vaccines among countries, but not the only one. Before vaccines are sent, countries must be able to distribute and administer them. Vaccinations — not vaccines — are what save lives. Support must be provided to countries like South Sudan, Malawi and Ivory Coast to upgrade their capacity to distribute vaccines...

..As the global supply of vaccines expands, vaccine manufacturers and nations expecting to have extra doses, including the United States and Britain, must decide which countries to help and how many doses to send to global organizations like Covax.

But if Covax's distribution criteria remain unresponsive to need, countries with spare doses should bypass the organization and distribute them where they will reduce deaths the most. It would be morally indefensible to give vaccines to Covax to send to countries with few cases or that are unable to deliver vaccines, while outbreaks rage elsewhere...

How to Allocate Vaccines Fairly: Covax's View

May 27, 2021 Letter to the Editor:

Re "[*The Wrong Way to Distribute Vaccines*](#)," by Ezekiel J. Emanuel and Govind Persad (*Opinion guest essay*, May 25):

The suggestion that it is unethical to allocate vaccines equitably across all nations when some countries are faring worse against the ravages of Covid-19 than others misses one crucial fact: Vaccines are at their most effective when preventing surges of the virus, not combating them once they have taken hold.

When outbreaks occur, the critical tools available to governments are of the nonpharmaceutical variety, such as lockdowns, distancing and mask wearing. Vaccines are also a part of the solution, but with up to three months needed for a two-dose Oxford/AstraZeneca vaccination, followed by a two-week wait in order to achieve full protection, they are not an acute intervention even if there are enough to go around.

We don't know where the next surge will hit or when the next variant will emerge, which is why Covax's goal to protect the most vulnerable everywhere is, at this stage of the pandemic, the right thing to do. This not only means maximizing the chances of survival for the health workers, elderly and vulnerable whose lives are most at risk, but also minimizing the chances that new, more dangerous variants will come along.

The real issue with vaccines today is not how to divvy up a small slice of the pie for less wealthy nations but how to make their slice bigger, which is why governments and manufacturers of vaccines must do everything in their power to get as many doses as possible to Covax now.

Seth Berkley

Soumya Swaminathan

Richard Hatchett

Dr. Berkley is chief executive of Gavi, the Vaccine Alliance. Dr. Swaminathan is chief scientist of the World Health Organization. Dr. Hatchett is chief executive of the Coalition for Epidemic Preparedness Innovations. Their organizations co-lead Covax.

Washington Post

<https://www.washingtonpost.com/>

Accessed 29 May 2021

[No new, unique, relevant content]

* * * *

Think Tanks et al

Brookings

<http://www.brookings.edu/>

Accessed 29 May 2021

Future Development

COVID-19 is a developing country pandemic

Indermit Gill and Philip Schellekens

Thursday, May 27, 2021

Center for Global Development [to 29 May 2021]

<http://www.cgdev.org/page/press-center>

Event

Developing a Plan to Vaccinate the World

6/2/21

While vaccine R&D stands out as a success in the ongoing response to COVID-19, there is still a long way to go to meet vaccination needs, particularly in low- and middle-income countries

To Increase Vaccine Manufacturing in LMICs, We Also Need to Strengthen Regulatory Capacity

May 25, 2021

A lot of recent discussions focus on how to expand COVID-19 vaccine manufacturing capacity in low- and middle-income countries (LMICs). The conversations highlight the importance of technology transfer and the capability of the tech transfer receiving sites (the facilities in these countries that would then produce vaccines locally), including having specialized equipment and personnel.

Javier Guzman and Prashant Yadav

Chatham House [to 29 May 2021]

<https://www.chathamhouse.org/>

Accessed 29 May 2021

[No new digest content]

CSIS

<https://www.csis.org/>

Accessed 29 May 2021

[No new digest content]

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

Accessed 29 May 2021

May 28, 2021 News Release

Vaccine Monitor: Vaccination Rates Continue to Inch Upwards Across Groups, Especially Among Hispanic Adults, But Few Who Are Eager to Get a Shot Remain Unvaccinated

4 in 10 Parents Say Their Adolescent Children Have Already Gotten a Shot or Will Do So Right Away; One Quarter of Parents of Children Under 12 Will Get Them Vaccinated as Soon as They Are Eligible
Few Unvaccinated Adults Say that CDC's Guidelines for Vaccinated Adults Make Them More...

May 26, 2021 News Release

The Pandemic's Impact on Children's Mental Health

The pandemic has taken a heavy toll on the nation's mental health, and a new issue brief shows that children are also facing worsening emotional and cognitive health. The brief examines factors contributing to worsening mental health and substance use outcomes among children and adolescents during the pandemic, looking closely...

* * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *
* * * *